


**CUMULATIVE
SUPPLEMENT 3
MARCH 2018**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2018

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**Cumulative Supplement 3
March 2018**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

38th EDITION

CUMULATIVE SUPPLEMENT 3
March 2018

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
SAGENT AGILA LLIC (SAGENT AGILA)	MYLAN ASI LLC (MYLAN ASI)
SAGENT AGILA LLC (SAGENT AGILA LLC)	MYLAN ASI LLC (MYLAN ASI)
SAGENT STRIDES LLC (SAGENT STRIDESC)	MYLAN ASI LLC (MYLAN ASI)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference

listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2017</u>	<u>MAR 2018</u>	<u>JUN 2018</u>	<u>SEP 2018</u>	<u>DEC 2018</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	19294	19359			
	2758	2763			
	(14.3%)	(14.3%)			
MULTISOURCE	16536	16596			
	(85.7%)	(85.7%)			
THERAPEUTICALLY EQUIVALENT	16431	16501			
	(85.2%)	(85.2%)			
NOT THERAPEUTICALLY EQUIVALENT	105	95			
	(0.5%)	(0.5%)			
EXCEPTIONS ¹	73	72			
	(0.4%)	(0.4%)			
NEW MOLECULAR ENTITIES APPROVED	25	6			
NUMBER OF APPLICANTS	1075	1084			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL
 ABACAVIR SULFATE
 AA AUROBINDO PHARMA LTD EQ 20MG BASE/ML A 077950 001 Mar 14, 2018 Feb NEWA

ABIRATERONE ACETATE

TABLET;ORAL
 ZYTIGA
 + JANSSEN BIOTECH 250MG N202379 001 Apr 28, 2011 Feb CHRS
 +! 500MG N202379 002 Apr 14, 2017 Feb CHRS

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
 APADAZ
 + KEMPARM 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
 BUTALBITAL AND ACETAMINOPHEN
 >A> MAYNE PHARMA INC 300MG;50MG A207313 001 Dec 27, 2017 Mar CAHN
 >D> MIKART INC 300MG;50MG A207313 001 Dec 27, 2017 Mar CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
 ACETAMINOPHEN AND CODEINE PHOSPHATE
 @ FOSUN PHARMA 300MG;30MG A081250 001 Jul 16, 1992 Jan CAHN
 @ 300MG;60MG A081249 001 Jul 16, 1992 Jan CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 >A> AA EPIC PHARMA LLC 325MG;5MG A203863 001 Mar 30, 2018 Mar NEWA
 >A> AA 325MG;7.5MG A203863 002 Mar 30, 2018 Mar NEWA
 >A> AA 325MG;10MG A203863 003 Mar 30, 2018 Mar NEWA
 >A> AA RHODES PHARMS 300MG;5MG A207808 001 Mar 30, 2018 Mar NEWA
 >A> AA 300MG;7.5MG A207808 002 Mar 30, 2018 Mar NEWA
 >A> AA 300MG;10MG A207808 003 Mar 30, 2018 Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL
 OXYCODONE AND ACETAMINOPHEN
 @ SPECGX LLC 325MG/5ML;5MG/5ML A040680 001 Sep 29, 2006 Jan DISC
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN
 @ VINTAGE PHARMS 325MG/5ML;5MG/5ML A203573 001 Dec 18, 2014 Jan DISC
 TABLET;ORAL
 OXYCODONE AND ACETAMINOPHEN
 AA ABHAI LLC 325MG;2.5MG A210644 001 Feb 09, 2018 Jan NEWA
 AA 325MG;5MG A210644 002 Feb 09, 2018 Jan NEWA
 AA 325MG;7.5MG A210644 003 Feb 09, 2018 Jan NEWA
 AA 325MG;10MG A210644 004 Feb 09, 2018 Jan NEWA
 >A> AA WES PHARMA INC 325MG;5MG A207510 001 Mar 21, 2018 Mar NEWA
 >A> AA 325MG;7.5MG A207510 002 Mar 21, 2018 Mar NEWA
 >A> AA 325MG;10MG A207510 003 Mar 21, 2018 Mar NEWA

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL
 ACETIC ACID 0.25% IN PLASTIC CONTAINER
 >D> AT ICU MEDICAL INC 250MG/100ML N017656 001 Mar CRLD
 >A> AT +! 250MG/100ML N017656 001 Mar CRLD
 SOLUTION/DROPS;OTIC
 ACETIC ACID
 AT RISING PHARMS INC 2% A207280 001 Mar 09, 2018 Feb NEWA

ACYCLOVIR

CAPSULE;ORAL
 ACYCLOVIR
 >D> @ HERITAGE PHARMS INC 200MG A074889 001 Oct 31, 1997 Mar CMFD
 >A> AB 200MG A074889 001 Oct 31, 1997 Mar CMFD

	OINTMENT; TOPICAL							
	ACYCLOVIR							
>A>	AB	ALEMBIC PHARMS LTD	5%	A209000	001	Apr 06, 2018	Mar	NEWA
		TABLET; ORAL						
		ACYCLOVIR						
	AB	YILING PHARM LTD	400MG	A210401	001	Mar 07, 2018	Feb	NEWA
	AB		800MG	A210401	002	Mar 07, 2018	Feb	NEWA
	<u>ADAPALENE; BENZOYL PEROXIDE</u>							
	GEL; TOPICAL							
	ADAPALENE AND BENZOYL PEROXIDE							
	AB	PERRIGO ISRAEL	0.1%;2.5%	A205033	001	Jan 23, 2018	Jan	NEWA
	AB	TARO	0.1%;2.5%	A206959	001	Jan 24, 2018	Jan	NEWA
	<u>ADENOSINE</u>							
	INJECTABLE; INJECTION							
	ADENOSINE							
	AP	GLAND PHARMA LTD	3MG/ML	A206778	001	Feb 16, 2018	Feb	NEWA
	<u>ALBUTEROL SULFATE</u>							
	TABLET; ORAL							
	ALBUTEROL SULFATE							
		@ YAOPHARMA CO LTD	EQ 2MG BASE	A072151	001	Dec 05, 1989	Jan	CAHN
		@	EQ 4MG BASE	A072152	001	Dec 05, 1989	Jan	CAHN
	<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>							
	SOLUTION; INHALATION							
	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
		@ FOSUN PHARMA	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Jan	CAHN
	<u>ALENDRONATE SODIUM</u>							
	TABLET; ORAL							
	ALENDRONATE SODIUM							
	AB	HANGZHOU BINJIANG	EQ 5MG BASE	A090258	001	Sep 24, 2009	Jan	CAHN
	AB		EQ 10MG BASE	A090258	002	Sep 24, 2009	Jan	CAHN
	AB		EQ 35MG BASE	A090258	003	Sep 24, 2009	Jan	CAHN
	AB		EQ 70MG BASE	A090258	004	Sep 24, 2009	Jan	CAHN
	<u>ALLOPURINOL</u>							
	TABLET; ORAL							
	ALLOPURINOL							
		@ FOSUN PHARMA	100MG	A070268	001	Dec 31, 1985	Jan	CAHN
	<u>ALOSETRON HYDROCHLORIDE</u>							
	TABLET; ORAL							
	ALOSETRON HYDROCHLORIDE							
	AB	PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	Feb	NEWA
	AB		EQ 1MG BASE	A206113	002	Feb 23, 2018	Feb	NEWA
	<u>AMANTADINE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	AMANTADINE HYDROCHLORIDE							
	AB	JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018	Jan	NEWA
	TABLET, EXTENDED RELEASE; ORAL							
	OSMOLEX ER							
	+	OSMOTICA PHARM	EQ 129MG BASE	N209410	001	Feb 16, 2018	Feb	NEWA
	+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Feb	NEWA
	+	!	EQ 258MG BASE	N209410	003	Feb 16, 2018	Feb	NEWA
	<u>AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE</u>							
	TABLET; ORAL							
	AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
		@ YAOPHARMA CO LTD	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991	Jan	CAHN
	<u>AMINO ACIDS</u>							
	INJECTABLE; INJECTION							
	AMINOSYN-HF 8%							
>D>		ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Mar	DISC
>A>		@	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Mar	DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	10MG	A 089399	002	Jul 14, 1987	Jan	CMFD
AB		25MG	A 089399	001	Jul 14, 1987	Jan	CMFD
AB		50MG	A 089399	003	Jul 14, 1987	Jan	CMFD
AB		75MG	A 089399	004	Jul 14, 1987	Jan	CMFD
AB		100MG	A 089399	005	Jul 14, 1987	Jan	CMFD
AB		150MG	A 089399	006	Jul 14, 1987	Jan	CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	FOSUN PHARMA	10MG; 2MG	A 071062	001	Nov 27, 1987	Jan	CAHN
@		10MG; 4MG	A 071862	001	Dec 21, 1987	Jan	CAHN
@		25MG; 4MG	A 071064	001	Nov 27, 1987	Jan	CAHN
@		50MG; 4MG	A 071863	001	Dec 21, 1987	Jan	CAHN
@	SANDOZ INC	25MG; 2MG	A 071063	001	Nov 27, 1987	Jan	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

@	YAOPHARMA CO LTD	EQ 2.5MG BASE	A 076859	001	Sep 10, 2007	Jan	CAHN
@		EQ 5MG BASE	A 076859	002	Sep 10, 2007	Jan	CAHN
@		EQ 10MG BASE	A 076859	003	Sep 10, 2007	Jan	CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A 204667	001	Apr 22, 2015	Feb	CAHN
----	-------	--------------------------------------	----------	-----	--------------	-----	------

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN

@	SUN PHARM INDS INC	EQ 12% BASE	N 020508	001	Aug 29, 1996	Feb	CAHN
---	--------------------	-------------	----------	-----	--------------	-----	------

LOTION; TOPICAL

LAC-HYDRIN

+	@	SUN PHARM INDS INC	EQ 12% BASE	N 019155	001	Apr 24, 1985	Feb	CAHN
---	---	--------------------	-------------	----------	-----	--------------	-----	------

AMOXAPINE

TABLET; ORAL

AMOXAPINE

>A>	WATSON LABS	25MG	A 072691	002	Aug 28, 1992	Mar	CMS1
>A>		50MG	A 072691	003	Aug 28, 1992	Mar	CMS1
>A>		100MG	A 072691	004	Aug 28, 1992	Mar	CMS1

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D>	AP	ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A 062797	001	Jul 12, 1993	Mar	DISC
>A>		@	EQ 125MG BASE/VIAL	A 062797	001	Jul 12, 1993	Mar	DISC

ANASTROZOLE

TABLET; ORAL

ARIMIDEX

AB	+	ANI PHARMS INC	1MG	N 020541	001	Dec 27, 1995	Jan	CAHN
----	---	----------------	-----	----------	-----	--------------	-----	------

ANGIOTENSIN II ACETATE

SOLUTION; IV (INFUSION)

GIAPREZA

+	!	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N 209360	001	Dec 21, 2017	Jan	CAIN
+	!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N 209360	002	Dec 21, 2017	Jan	CAIN

APALUTAMIDE

TABLET; ORAL

ERLEADA

+	!	JANSSEN BIOTECH	60MG	N 210951	001	Feb 14, 2018	Feb	NEWA
---	---	-----------------	------	----------	-----	--------------	-----	------

APREPITANT

	CAPSULE;ORAL						
	APREPITANT						
AB	GLENMARK PHARMS SA	40MG	A207777	001	Oct 12, 2017	Jan	CAHN
AB		80MG	A207777	002	Oct 12, 2017	Jan	CAHN
AB		125MG	A207777	003	Oct 12, 2017	Jan	CAHN

ARGATROBAN

	INJECTABLE;INJECTION						
	ARGATROBAN						
AP	AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698	001	Jan 26, 2018	Jan	NEWA

ARMODAFINIL

	TABLET;ORAL						
	ARMODAFINIL						
AB	AUROBINDO PHARMA LTD	50MG	A206069	001	Mar 06, 2018	Feb	NEWA
AB		150MG	A206069	002	Mar 06, 2018	Feb	NEWA
AB		250MG	A206069	003	Mar 06, 2018	Feb	NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

	TABLET;ORAL						
	BUTALBITAL, ASPIRIN AND CAFFEINE						
	@ FOSUN PHARMA	325MG;50MG;40MG	A086398	002	Apr 06, 1984	Jan	CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

	TABLET;ORAL						
	ORPHENGESIC						
	@ GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998	Feb	CAHN
	ORPHENGESIC FORTE						
	@ GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998	Feb	CAHN

ASPIRIN; CARISOPRODOL

	TABLET;ORAL						
	CARISOPRODOL AND ASPIRIN						
	@ OXFORD PHARMS	325MG;200MG	A040252	001	Dec 10, 1997	Jan	DISC

ATOMOXETINE HYDROCHLORIDE

	CAPSULE;ORAL						
	ATOMOXETINE HYDROCHLORIDE						
AB	DR REDDYS LABS LTD	10MG	A090609	001	Feb 23, 2018	Feb	NEWA
AB		18MG	A090609	002	Feb 23, 2018	Feb	NEWA
AB		25MG	A090609	003	Feb 23, 2018	Feb	NEWA
AB		40MG	A090609	004	Feb 23, 2018	Feb	NEWA
AB		60MG	A090609	005	Feb 23, 2018	Feb	NEWA
AB		80MG	A090609	006	Feb 23, 2018	Feb	NEWA
AB		100MG	A090609	007	Feb 23, 2018	Feb	NEWA

ATORVASTATIN CALCIUM

	TABLET;ORAL							
	ATORVASTATIN CALCIUM							
>A>	AB	ACCORD HLTHCARE	EQ 10MG BASE	A207687	001	Mar 30, 2018	Mar	NEWA
>A>	AB		EQ 20MG BASE	A207687	002	Mar 30, 2018	Mar	NEWA
>A>	AB		EQ 40MG BASE	A207687	003	Mar 30, 2018	Mar	NEWA
>A>	AB		EQ 80MG BASE	A207687	004	Mar 30, 2018	Mar	NEWA

ATROPINE SULFATE

	SOLUTION;IV (INFUSTION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL							
	ATROPINE SULFATE							
	+!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	Jan	NEWA
	SOLUTION/DROPS;OPHTHALMIC							
	ISOPTO ATROPINE							
	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Feb	CAHN	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

	TABLET;ORAL						
	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE						
	@ FOSUN PHARMA	0.025MG;2.5MG	A086173	001		Jan	CAHN
	LONOX						
	@ FOSUN PHARMA	0.025MG;2.5MG	A085311	002		Jan	CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+! ALLERGAN SALES LLC EQ 0.5GM BASE;2GM/VIAL N206494 001 Feb 25, 2015 Jan CAHN

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

>A> AB EPIC PHARMA LLC EQ 100MG BASE/5ML A207531 001 Apr 09, 2018 Mar NEWA
 >A> AB EQ 200MG BASE/5ML A207531 002 Apr 09, 2018 Mar NEWA

TABLET; ORAL

AZITHROMYCIN

>D> AB APOTEX CORP EQ 250MG BASE A065507 001 Jul 13, 2011 Mar DISC
 >A> @ EQ 250MG BASE A065507 001 Jul 13, 2011 Mar DISC
 >D> AB EQ 500MG BASE A065509 001 Jul 13, 2011 Mar DISC
 >A> @ EQ 500MG BASE A065509 001 Jul 13, 2011 Mar DISC
 >D> AB EQ 600MG BASE A065508 001 Jul 13, 2011 Mar DISC
 >A> @ EQ 600MG BASE A065508 001 Jul 13, 2011 Mar DISC

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

@ MYLAN ASI 50,000 UNITS/VIAL A090211 001 May 11, 2010 Jan DISC

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

>A> AP MYLAN LABS LTD 0.5MG/ML A209592 001 Mar 21, 2018 Mar NEWA
 AP 1MG/ML A209594 001 Mar 06, 2018 Feb NEWA
 >A> AP 2MG/ML A209592 002 Mar 21, 2018 Mar NEWA
 GABLOFEN
 AP +! PIRAMAL CRITICAL 1MG/ML N022462 004 Jun 22, 2012 Feb CFTG

BIARIUM SULFATE

SUSPENSION; ORAL

VARIBAR HONEY

>A> +! BRACCO 40% (100GM/250ML) N208143 007 Mar 26, 2018 Mar NEWA
 VARIBAR THIN HONEY
 +! BRACCO 40% (100GM/250ML) N208143 006 Jan 23, 2018 Jan NEWA

BECLMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR REDIHALER

+! NORTON WATERFORD 0.04MG/INH N207921 001 Aug 03, 2017 Jan CHRS

BENZAEPRIIL HYDROCHLORIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE

>A> AB CASI PHARMS INC 5MG A076402 001 Feb 11, 2004 Mar CAHN
 >A> AB 10MG A076402 002 Feb 11, 2004 Mar CAHN
 >A> AB 20MG A076402 003 Feb 11, 2004 Mar CAHN
 >A> AB 40MG A076402 004 Feb 11, 2004 Mar CAHN
 >D> AB SANDOZ 5MG A076402 001 Feb 11, 2004 Mar CAHN
 >D> AB 10MG A076402 002 Feb 11, 2004 Mar CAHN
 >D> AB 20MG A076402 003 Feb 11, 2004 Mar CAHN
 >D> AB 40MG A076402 004 Feb 11, 2004 Mar CAHN

BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D> @ SUN PHARM INDS LTD 5MG;6.25MG A077483 001 Sep 08, 2005 Mar DISC
 >A> @ 5MG;6.25MG A077483 001 Sep 08, 2005 Mar DISC

BENZONATATE

CAPSULE; ORAL

BENZONATATE

>A> AA CSPEC NBP PHARM CO 100MG A202765 002 Aug 25, 2017 Mar NEWA

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

@ CHARTWELL RX

1MG

A 081264 001 Jan 23, 1992 Jan CAHN

@

2MG

A 081265 001 Jan 23, 1992 Jan CAHN

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB HI-TECH PHARMACAL EQ 0.05% BASE

A 209896 001 Feb 06, 2018 Jan NEWA

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB TELIGENT PHARMA INC EQ 0.05% BASE

A 206389 001 Feb 13, 2018 Jan NEWA

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETA-VAL

@ G AND W LABS INC

EQ 0.1% BASE

A 070072 001 Jun 27, 1985 Jan DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETOPTIC

AT +! SANDOZ INC EQ 0.5% BASE

N 019270 001 Aug 30, 1985 Jan CAHN

BICALUTAMIDE

TABLET; ORAL

CASODEX

AB +! ANI PHARMS INC 50MG

N 020498 001 Oct 04, 1995 Jan CAHN

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

BIKTARVY

+! GILEAD SCIENCES INC EQ 50MG BASE; 200MG; EQ 25MG BASE

N 210251 001 Feb 07, 2018 Feb NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+! ALLERGAN SALES LLC 140MG; 125MG; 125MG

N 050786 001 Sep 28, 2006 Jan CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

>A> AB CASI PHARMS INC 5MG

A 075643 001 Nov 16, 2000 Mar CAHN

>A> AB 10MG

A 075643 002 Nov 16, 2000 Mar CAHN

>D> AB SANDOZ 5MG

A 075643 001 Nov 16, 2000 Mar CAHN

>D> AB 10MG

A 075643 002 Nov 16, 2000 Mar CAHN

BIVALIRUDIN

SOLUTION; IV (INFUSION)

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP 250MG/50ML (5MG/ML)

N 208374 001 Dec 21, 2017 Jan CAHN

+! 500MG/100ML (5MG/ML)

N 208374 002 Dec 21, 2017 Jan CAHN

BUMETANIDE

TABLET; ORAL

BUMETANIDE

AB UPSHER-SMITH LABS 0.5MG

A 209916 001 Jan 23, 2018 Jan NEWA

AB 1MG

A 209916 002 Jan 23, 2018 Jan NEWA

AB 2MG

A 209916 003 Jan 23, 2018 Jan NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>A> AB CASI PHARMS INC EQ 2MG BASE

A 090279 001 Jun 10, 2015 Mar CAHN

>A> AB EQ 8MG BASE

A 090279 002 Jun 10, 2015 Mar CAHN

>D> AB SANDOZ INC EQ 2MG BASE

A 090279 001 Jun 10, 2015 Mar CAHN

>D> AB EQ 8MG BASE

A 090279 002 Jun 10, 2015 Mar CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

AB2 SCIEGEN PHARMS INC 150MG A206122 001 Aug 17, 2016 Jan CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB AUROBINDO PHARMA LTD 5MG A078246 001 Feb 27, 2009 Feb CAHN
 AB 10MG A078246 002 Feb 27, 2009 Feb CAHN
 AB 15MG A078246 003 Feb 27, 2009 Feb CAHN
 AB 30MG A078246 004 Feb 27, 2009 Feb CAHN
 @ FOSUN PHARMA 5MG A075413 001 Mar 19, 2002 Jan CAHN
 @ 10MG A075413 002 Mar 19, 2002 Jan CAHN
 @ 15MG A075413 003 Mar 19, 2002 Jan CAHN

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION
BUTORPHANOL TARTRATE PRESERVATIVE FREE

>D> AP HOSPIRA 1MG/ML A074626 001 Jan 23, 1997 Mar CHRS
 >A> AP ! 1MG/ML A074626 001 Jan 23, 1997 Mar CHRS
 >D> AP 2MG/ML A074626 002 Jan 23, 1997 Mar CHRS
 >A> AP ! 2MG/ML A074626 002 Jan 23, 1997 Mar CHRS
 STADOL
 >D> @ APOTHECON 2MG/ML N017857 004 Mar CRLD
 >A> + @ 2MG/ML N017857 004 Mar CRLD
 STADOL PRESERVATIVE FREE
 >D> @ APOTHECON 1MG/ML N017857 001 Mar CRLD
 >A> + @ 1MG/ML N017857 001 Mar CRLD
 >D> @ 2MG/ML N017857 002 Mar CRLD
 >A> + @ 2MG/ML N017857 002 Mar CRLD

CABERGOLINE

TABLET;ORAL
CABERGOLINE

>D> AB APOTEX CORP 0.5MG A201503 001 Mar 08, 2013 Mar DISC
 >A> @ 0.5MG A201503 001 Mar 08, 2013 Mar DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
 + @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;104MG/100ML;6 N019685 005 Oct 17, 1988 Jan CRLD
 00MG/100ML;310MG/100ML
 + @ 20MG/100ML;5GM/100ML;179MG/100ML;6 N019685 006 Oct 17, 1988 Jan CRLD
 00MG/100ML;310MG/100ML
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
 + @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;254MG/100ML;6 N019685 007 Oct 17, 1988 Jan CRLD
 00MG/100ML;310MG/100ML
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
 AP + ICU MEDICAL INC 20MG/100ML;5GM/100ML;179MG/100ML;6 N019685 002 Oct 17, 1988 Jan CRLD
 00MG/100ML;310MG/100ML
 + @ 20MG/100ML;5GM/100ML;328MG/100ML;6 N019685 008 Oct 17, 1988 Jan DISC
 00MG/100ML;310MG/100ML
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
 + @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;254MG/100ML;6 N019685 003 Oct 17, 1988 Jan CRLD
 00MG/100ML;310MG/100ML
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
 + @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;328MG/100ML;6 N019685 004 Oct 17, 1988 Jan DISC
 00MG/100ML;310MG/100ML
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
 + @ ICU MEDICAL INC 20MG/100ML;5GM/100ML;104MG/100ML;6 N019685 001 Oct 17, 1988 Jan CRLD
 00MG/100ML;310MG/100ML

CANDESARTAN CILEXETIL

TABLET;ORAL
ATACAND

AB + ANI PHARMS INC 4MG N020838 001 Jun 04, 1998 Jan CAHN
 AB + 8MG N020838 002 Jun 04, 1998 Jan CAHN
 AB + 16MG N020838 003 Jun 04, 1998 Jan CAHN
 AB +! 32MG N020838 004 Jun 04, 1998 Jan CAHN
 CANDESARTAN CILEXETIL
 >D> AB APOTEX INC 4MG A202079 001 Jan 10, 2014 Mar DISC
 >A> @ 4MG A202079 001 Jan 10, 2014 Mar DISC

TABLET;ORAL

CANDESARTAN CILEXETIL

>D>	AB		8MG	A202079	002	Jan 10, 2014	Mar	DISC
>A>	@		8MG	A202079	002	Jan 10, 2014	Mar	DISC
>D>	AB		16MG	A202079	003	Jan 10, 2014	Mar	DISC
>A>	@		16MG	A202079	003	Jan 10, 2014	Mar	DISC
>D>	AB		32MG	A202079	004	Jan 10, 2014	Mar	DISC
>A>	@		32MG	A202079	004	Jan 10, 2014	Mar	DISC

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ATACAND HCT

AB	+	ANI PHARMS INC	16MG;12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN
AB	+		32MG;12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN
AB	+	!	32MG;25MG	N021093	003	May 16, 2008	Feb	CAHN

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

>D>	AB	APOTEX INC	16MG;12.5MG	A202884	001	Dec 04, 2012	Mar	DISC
>A>	@		16MG;12.5MG	A202884	001	Dec 04, 2012	Mar	DISC
>D>	AB		32MG;12.5MG	A202884	002	Dec 04, 2012	Mar	DISC
>A>	@		32MG;12.5MG	A202884	002	Dec 04, 2012	Mar	DISC
>D>	AB		32MG;25MG	A202884	003	Jun 03, 2013	Mar	DISC
>A>	@		32MG;25MG	A202884	003	Jun 03, 2013	Mar	DISC
>A>	AB	PRINSTON INC	16MG;12.5MG	A207455	001	Apr 11, 2018	Mar	NEWA
>A>	AB		32MG;12.5MG	A207455	002	Apr 11, 2018	Mar	NEWA
>A>	AB		32MG;25MG	A207455	003	Apr 11, 2018	Mar	NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@	YAOPHARMA CO LTD	12.5MG	A074363	001	Nov 09, 1995	Jan	CAHN
@		12.5MG	A074519	001	Feb 13, 1996	Jan	CAHN
@		25MG	A074363	002	Nov 09, 1995	Jan	CAHN
@		25MG	A074519	002	Feb 13, 1996	Jan	CAHN
@		50MG	A074363	003	Nov 09, 1995	Jan	CAHN
@		50MG	A074519	003	Feb 13, 1996	Jan	CAHN
@		100MG	A074363	004	Nov 09, 1995	Jan	CAHN
@		100MG	A074519	004	Feb 13, 1996	Jan	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Jan	DISC
@		25MG;25MG	A074827	002	Dec 29, 1997	Jan	DISC
@		50MG;15MG	A074827	004	Dec 29, 1997	Jan	DISC
@		50MG;25MG	A074827	003	Dec 29, 1997	Jan	DISC
	MYLAN	25MG;15MG	A074896	001	Dec 29, 1997	Jan	CTEC
!		25MG;25MG	A074896	002	Dec 29, 1997	Jan	CTEC
!		50MG;15MG	A074896	004	Dec 29, 1997	Jan	CTEC
		50MG;25MG	A074896	003	Dec 29, 1997	Jan	CTEC

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

VRAYLAR

+	ALLERGAN SALES LLC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Jan	CAHN
+		EQ 3MG BASE	N204370	002	Sep 17, 2015	Jan	CAHN
+		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Jan	CAHN
+	!	EQ 6MG BASE	N204370	004	Sep 17, 2015	Jan	CAHN

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

@	FOSUN PHARMA	350MG	A081025	001	Apr 13, 1989	Jan	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

CARVEDILOL

TABLET;ORAL

CARVEDILOL

>A>	AB	CHARTWELL MOLECULAR	3.125MG	A077474	001	Sep 05, 2007	Mar	CAHN
>A>	AB		6.25MG	A077474	002	Sep 05, 2007	Mar	CAHN
>A>	AB		12.5MG	A077474	003	Sep 05, 2007	Mar	CAHN
>A>	AB		25MG	A077474	004	Sep 05, 2007	Mar	CAHN
>D>	AB	CIPLA LTD	3.125MG	A077474	001	Sep 05, 2007	Mar	CAHN
>D>	AB		6.25MG	A077474	002	Sep 05, 2007	Mar	CAHN
>D>	AB		12.5MG	A077474	003	Sep 05, 2007	Mar	CAHN

	TABLET;ORAL								
	CARVEDILOL								
>D>	AB	25MG	A077474	004	Sep 05, 2007	Mar	CAHN		
	<u>CEFEPIME HYDROCHLORIDE</u>								
	INJECTABLE; INJECTION								
	CEFEPIME HYDROCHLORIDE								
	@	FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291	001	Dec 21, 2010	Jan	CAHN	
	@		EQ 1GM BASE/VIAL	A090291	002	Dec 21, 2010	Jan	CAHN	
	@		EQ 2GM BASE/VIAL	A090291	003	Dec 21, 2010	Jan	CAHN	
	<u>CEFOTAXIME SODIUM</u>								
	INJECTABLE; INJECTION								
	CEFOTAXIME SODIUM								
	@	LUPIN	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003	Feb	DISC	
	@		EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003	Feb	DISC	
	@		EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003	Feb	DISC	
	<u>CEFPROZIL</u>								
	TABLET;ORAL								
	CEFPROZIL								
>A>	AB	CASI PHARMS INC	250MG	A065235	001	Nov 14, 2005	Mar	CAHN	
>A>	AB		500MG	A065235	002	Nov 14, 2005	Mar	CAHN	
>D>	AB	SANDOZ	250MG	A065235	001	Nov 14, 2005	Mar	CAHN	
>D>	AB		500MG	A065235	002	Nov 14, 2005	Mar	CAHN	
	<u>CEFTAROLINE FOSAMIL</u>								
	POWDER; IV (INFUSION)								
	TEFLARO								
	+	ALLERGAN SALES LLC	400MG/VIAL	N200327	001	Oct 29, 2010	Jan	CAHN	
	+	!	600MG/VIAL	N200327	002	Oct 29, 2010	Jan	CAHN	
	<u>CEFTIBUTEN DIHYDRATE</u>								
	CAPSULE;ORAL								
	CEDAX								
	@	SI PHARMS	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jan	CAHN	
	FOR SUSPENSION;ORAL								
	CEDAX								
	+	@	SI PHARMS	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jan	CAHN
	+	@		EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jan	CAHN
	<u>CEFTRIAZONE SODIUM</u>								
	INJECTABLE; INJECTION								
	CEFTRIAZONE								
	@	LUPIN	EQ 10GM BASE/VIAL	A065263	001	Sep 12, 2006	Feb	DISC	
	<u>CEFUROXIME AXETIL</u>								
	TABLET;ORAL								
	CEFUROXIME AXETIL								
	@	FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003	Jan	CAHN	
	@		EQ 500MG BASE	A065126	002	Oct 28, 2003	Jan	CAHN	
	<u>CELECOXIB</u>								
	CAPSULE;ORAL								
	CELECOXIB								
AB		CSPC OUYI PHARM CO	50MG	A210071	001	Jan 23, 2018	Jan	NEWA	
AB			100MG	A210071	002	Jan 23, 2018	Jan	NEWA	
AB			200MG	A210071	003	Jan 23, 2018	Jan	NEWA	
	<u>CEVIMELINE HYDROCHLORIDE</u>								
	CAPSULE;ORAL								
	CEVIMELINE HYDROCHLORIDE								
>D>	AB	APOTEX INC	30MG	A091260	001	Aug 25, 2011	Mar	DISC	
>A>		@	30MG	A091260	001	Aug 25, 2011	Mar	DISC	
	<u>CHLORPROMAZINE HYDROCHLORIDE</u>								
	CONCENTRATE;ORAL								
	SONAZINE								
	@	FOSUN PHARMA	30MG/ML	A080983	004		Jan	CAHN	
	@		100MG/ML	A080983	005		Jan	CAHN	

	SYRUP;ORAL								
	SONAZINE								
	@ FOSUN PHARMA	10MG/5ML		A 083040	001			Jan	CAHN
>D>	<u>CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE</u>								
>D>	TABLET;ORAL								
>D>	CLORPRES								
>D>	MYLAN	15MG;0.1MG		A 071325	003	Feb 09, 1987		Mar	DISC
>A>	@	15MG;0.1MG		A 071325	003	Feb 09, 1987		Mar	DISC
>D>		15MG;0.2MG		A 071325	002	Feb 09, 1987		Mar	DISC
>A>	@	15MG;0.2MG		A 071325	002	Feb 09, 1987		Mar	DISC
>D>	!	15MG;0.3MG		A 071325	001	Feb 09, 1987		Mar	DISC
>A>	@	15MG;0.3MG		A 071325	001	Feb 09, 1987		Mar	DISC
	<u>CICLOPIROX</u>								
	SHAMPOO;TOPICAL								
	CICLOPIROX								
>A>	AT	TELIGENT PHARMA INC	1%	A 209975	001	Apr 05, 2018		Mar	NEWA
	SOLUTION;TOPICAL								
	CICLOPIROX								
	AT	INGENUS PHARMS LLC	8%	A 078124	001	Sep 18, 2007		Jan	CAHN
	<u>CILOSTAZOL</u>								
	TABLET;ORAL								
	CILOSTAZOL								
>A>	AB	CASI PHARMS INC	50MG	A 077310	001	Nov 08, 2005		Mar	CAHN
>A>	AB		100MG	A 077021	001	Nov 23, 2004		Mar	CAHN
>D>	AB	SANDOZ	50MG	A 077310	001	Nov 08, 2005		Mar	CAHN
>D>	AB		100MG	A 077021	001	Nov 23, 2004		Mar	CAHN
	<u>CIMETIDINE</u>								
	TABLET;ORAL								
	CIMETIDINE								
	@ CHARTWELL MOLECULES	200MG		A 074329	002	May 17, 1994		Jan	CMS1
	@	300MG		A 074329	003	May 17, 1994		Jan	CMS1
	@	400MG		A 074329	004	May 17, 1994		Jan	CMS1
	@ YAOPHARMA CO LTD	200MG		A 074100	001	Jan 31, 1995		Jan	CAHN
	@	300MG		A 074100	002	Jan 31, 1995		Jan	CAHN
	@	400MG		A 074100	003	Jan 31, 1995		Jan	CAHN
	@	800MG		A 074100	004	Jan 31, 1995		Jan	CAHN
	<u>CINACALCET HYDROCHLORIDE</u>								
	TABLET;ORAL								
	CINACALCET HYDROCHLORIDE								
AB		AUROBINDO PHARMA LTD	EQ 30MG BASE	A 206125	001	Mar 08, 2018		Feb	NEWA
AB			EQ 60MG BASE	A 206125	002	Mar 08, 2018		Feb	NEWA
AB			EQ 90MG BASE	A 206125	003	Mar 08, 2018		Feb	NEWA
AB		CIPLA LTD	EQ 30MG BASE	A 208915	001	Mar 08, 2018		Feb	NEWA
AB			EQ 60MG BASE	A 208915	002	Mar 08, 2018		Feb	NEWA
AB			EQ 90MG BASE	A 208915	003	Mar 08, 2018		Feb	NEWA
		SENSIPAR							
AB	+	AMGEN	EQ 30MG BASE	N 021688	001	Mar 08, 2004		Feb	CFTG
AB	+		EQ 60MG BASE	N 021688	002	Mar 08, 2004		Feb	CFTG
AB	+	!	EQ 90MG BASE	N 021688	003	Mar 08, 2004		Feb	CFTG
	<u>CIPROFLOXACIN</u>								
	INJECTABLE;INJECTION								
	CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER								
AP		INFORLIFE	200MG/100ML	A 078252	001	Mar 18, 2008		Jan	CAHN
AP			400MG/200ML	A 078252	002	Mar 18, 2008		Jan	CAHN
	<u>CIPROFLOXACIN HYDROCHLORIDE</u>								
	TABLET;ORAL								
	CIPRO								
>D>	AB	+	BAYER HLTHCARE	EQ 100MG BASE	N 019537	001	Apr 08, 1996	Mar	DISC
>A>		+	@	EQ 100MG BASE	N 019537	001	Apr 08, 1996	Mar	DISC
>D>	AB	+		EQ 750MG BASE	N 019537	004	Oct 22, 1987	Mar	DISC
>A>		+	@	EQ 750MG BASE	N 019537	004	Oct 22, 1987	Mar	DISC
			CIPROFLOXACIN HYDROCHLORIDE						
			@ FOSUN PHARMA	EQ 250MG BASE	A 076593	002	Jun 09, 2004	Jan	CAHN
			@	EQ 500MG BASE	A 076593	003	Jun 09, 2004	Jan	CAHN
			@	EQ 750MG BASE	A 076593	004	Jun 09, 2004	Jan	CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
CIPROFLOXACIN EXTENDED RELEASE

@ FOSUN PHARMA 212.6MG;EQ 287.5MG BASE A078712 001 Dec 11, 2007 Jan CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION
CISATRACURIUM BESYLATE

>A> AP HOSPIRA INC EQ 2MG BASE/ML A203236 001 Mar 30, 2018 Mar NEWA
>A> AP EQ 2MG BASE/ML A203238 001 Mar 30, 2018 Mar NEWA
>A> AP EQ 10MG BASE/ML A203236 002 Mar 30, 2018 Mar NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL
CELEXA

AB + ALLERGAN SALES LLC EQ 10MG BASE N020822 001 Apr 27, 2000 Jan CAHN
AB + EQ 20MG BASE N020822 002 Jul 17, 1998 Jan CAHN
AB +! EQ 40MG BASE N020822 003 Jul 17, 1998 Jan CAHN
@ EQ 60MG BASE N020822 004 Jul 17, 1998 Jan CAHN
CITALOPRAM HYDROBROMIDE
>A> AB CHARTWELL MOLECULAR EQ 10MG BASE A077044 001 Nov 05, 2004 Mar CAHN
>A> AB EQ 20MG BASE A077044 002 Nov 05, 2004 Mar CAHN
>A> AB EQ 40MG BASE A077044 003 Nov 05, 2004 Mar CAHN
>D> AB CIPLA LTD EQ 10MG BASE A077044 001 Nov 05, 2004 Mar CAHN
>D> AB EQ 20MG BASE A077044 002 Nov 05, 2004 Mar CAHN
>D> AB EQ 40MG BASE A077044 003 Nov 05, 2004 Mar CAHN
@ FOSUN PHARMA EQ 10MG BASE A077035 001 Oct 28, 2004 Jan CAHN
@ EQ 10MG BASE A077040 001 Aug 17, 2005 Jan CAHN
@ EQ 20MG BASE A077035 002 Oct 28, 2004 Jan CAHN
@ EQ 20MG BASE A077040 002 Aug 17, 2005 Jan CAHN
@ EQ 40MG BASE A077035 003 Oct 28, 2004 Jan CAHN
@ EQ 40MG BASE A077040 003 Aug 17, 2005 Jan CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A> @ ABBOTT LABS EQ 6MG BASE/ML A065027 001 Jun 29, 2001 Mar CAHN
>A> @ EQ 12MG BASE/ML A065027 002 Jun 29, 2001 Mar CAHN
>A> @ EQ 18MG BASE/ML A065027 003 Jun 29, 2001 Mar CAHN
>D> @ ABBVIE EQ 6MG BASE/ML A065027 001 Jun 29, 2001 Mar CAHN
>D> @ EQ 12MG BASE/ML A065027 002 Jun 29, 2001 Mar CAHN
>D> @ EQ 18MG BASE/ML A065027 003 Jun 29, 2001 Mar CAHN

SOLUTION;TOPICAL
CLINDAMYCIN PHOSPHATE

AT GLASSHOUSE PHARMS EQ 1% BASE A209846 001 Feb 08, 2018 Jan NEWA

CLOBETASOL PROPIONATE

CREAM;TOPICAL
CLOBETASOL PROPIONATE

AB1 LUPIN LTD 0.05% A210208 001 Jan 30, 2018 Jan NEWA
IMPOYZ
+! ENCORE DERMAT 0.025% N209483 001 Nov 28, 2017 Jan CAHN

SPRAY;TOPICAL
CLOBETASOL PROPIONATE

>A> AT GLENMARK PHARMS 0.05% A209004 001 Mar 26, 2018 Mar NEWA
>A> AT LUPIN LTD 0.05% A208125 001 Mar 26, 2018 Mar NEWA
>A> AT TARO 0.05% A208842 001 Mar 26, 2018 Mar NEWA

CLONIDINE HYDROCHLORIDE

TABLET;ORAL
CLONIDINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 0.1MG A070886 002 Aug 31, 1988 Jan CMS1
@ 0.3MG A070886 003 Aug 31, 1988 Jan CMS1

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

AB1 JUBILANT GENERICS 0.1MG A210338 001 Jan 29, 2018 Jan NEWA

CLOZAPINE

TABLET; ORAL

CLOZAPINE

@	ZYDUS PHARMS USA INC	25MG	A209480	001	Dec 06, 2017	Feb	DISC
@		50MG	A209480	002	Dec 06, 2017	Feb	DISC
@		100MG	A209480	003	Dec 06, 2017	Feb	DISC
@		200MG	A209480	004	Dec 06, 2017	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

CLOZAPINE

>A>	AB	BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018	Mar	NEWA
		FAZACLO ODT						
>D>	+	JAZZ PHARMS III	12.5MG	N021590	004	May 30, 2007	Mar	CTEC
>A>	AB	+	12.5MG	N021590	004	May 30, 2007	Mar	CTEC

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

FULYZAQ

>D>								
>D>	+	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Mar	CTNA
>A>		MYTESI						
>A>	+	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Mar	CTNA

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

>A>		@ FERA PHARMS LLC	10MG/ML	A075437	001	Apr 21, 2000	Mar	CAHN
>D>		@ PHARMASCIENCE INC	10MG/ML	A075437	001	Apr 21, 2000	Mar	CAHN

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

AT		SANDOZ INC	4%	A075282	001	Jun 16, 1999	Jan	CAHN
----	--	------------	----	---------	-----	--------------	-----	------

CROTAMITON

CREAM; TOPICAL

EURAX

+	!	SUN PHARM INDS INC	10%	N006927	001		Feb	CAHN
---	---	--------------------	-----	---------	-----	--	-----	------

LOTION; TOPICAL

EURAX

AT	+	!	SUN PHARM INDS INC	10%	N009112	003		Feb	CAHN
----	---	---	--------------------	-----	---------	-----	--	-----	------

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOGYL

AT	!	ALCON LABS INC	0.5%	A084109	001		Feb	CAHN
AT	!		1%	A084110	001		Feb	CAHN
	!		2%	A084108	001		Feb	CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

!	ALCON LABS INC	0.2%;1%	A084300	001		Feb	CAHN
---	----------------	---------	---------	-----	--	-----	------

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

>A>	AB	AMERIGEN PHARMS LTD	25MG	A207014	001	Mar 19, 2018	Mar	NEWA	
>A>	AB		50MG	A207014	002	Mar 19, 2018	Mar	NEWA	
>D>	+	WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Mar	CFTG	
>A>	AB	+	25MG	N203856	001	Sep 16, 2013	Mar	CFTG	
>D>	+	!	50MG	N203856	002	Sep 16, 2013	Mar	CFTG	
>A>	AB	+	!	50MG	N203856	002	Sep 16, 2013	Mar	CFTG

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

	@	FOSUN PHARMA	4MG	A086808	001		Jan	CAHN
AA		MOUNTAIN	4MG	A040537	001	Sep 30, 2003	Jan	CAHN
>A>	AA	STRIDES PHARMA	4MG	A209172	001	Apr 11, 2018	Mar	NEWA

CYTARABINEINJECTABLE; INJECTION
CYTARABINE

AP MYLAN LABS LTD 20MG/ML A200916 001 Dec 13, 2011 Jan CAHN

>A> DAPAGLIFLOZIN

>A> TABLET; ORAL

>A> FARXIGA

>A> + ASTRAZENECA AB 5MG N202293 001 Jan 08, 2014 Mar CAIN

>A> +! 10MG N202293 002 Jan 08, 2014 Mar CAIN

>D> DAPAGLIFLOZIN PROPANEDIOL

>D> TABLET; ORAL

>D> FARXIGA

>D> + ASTRAZENECA AB EQ 5MG BASE N202293 001 Jan 08, 2014 Mar CAIN

>D> +! EQ 10MG BASE N202293 002 Jan 08, 2014 Mar CAIN

>D> DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE

>D> TABLET, EXTENDED RELEASE; ORAL

>D> XIGDUO XR

>D> + ASTRAZENECA AB EQ 2.5MG BASE; 1GM N205649 005 Jul 28, 2017 Mar CAIN

>D> + EQ 5MG BASE; 500MG N205649 001 Oct 29, 2014 Mar CAIN

>D> + EQ 5MG BASE; 1GM N205649 002 Oct 29, 2014 Mar CAIN

>D> + EQ 10MG BASE; 500MG N205649 003 Oct 29, 2014 Mar CAIN

>D> +! EQ 10MG BASE; 1GM N205649 004 Oct 29, 2014 Mar CAIN

>D> DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE

>D> TABLET; ORAL

>D> QTERN

>D> +! ASTRAZENECA AB EQ 10MG BASE; EQ 5MG BASE N209091 001 Feb 27, 2017 Mar CAIN

>A> DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

>A> TABLET, EXTENDED RELEASE; ORAL

>A> XIGDUO XR

>A> + ASTRAZENECA AB 2.5MG; 1GM N205649 005 Jul 28, 2017 Mar CAIN

>A> + 5MG; 500MG N205649 001 Oct 29, 2014 Mar CAIN

>A> + 5MG; 1GM N205649 002 Oct 29, 2014 Mar CAIN

>A> + 10MG; 500MG N205649 003 Oct 29, 2014 Mar CAIN

>A> +! 10MG; 1GM N205649 004 Oct 29, 2014 Mar CAIN

>A> DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

>A> TABLET; ORAL

>A> QTERN

>A> +! ASTRAZENECA AB 10MG; EQ 5MG BASE N209091 001 Feb 27, 2017 Mar CAIN

DAPTOMYCINPOWDER; INTRAVENOUS
DAPTOMYCIN

>A> AP FRESENIUS KABI USA 500MG/VIAL A206077 001 Apr 11, 2018 Mar NEWA

AP TEVA PHARMS USA 500MG/VIAL A091039 001 Mar 25, 2016 Feb CAHN

DECITABINEINJECTABLE; INTRAVENOUS
DECITABINE

>A> AP SAGENT PHARMS 50MG/VIAL A207100 001 Mar 16, 2018 Mar NEWA

DESFLURANELIQUID; INHALATION
DESFLURANE

AN SHANGHAI HENGRUI 100% A208234 001 Feb 26, 2018 Feb NEWA

AN +! BAXTER HLTHCARE 100% N020118 001 Sep 18, 1992 Feb CFTG

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
DESIPRAMINE HYDROCHLORIDE

AB MOUNTAIN 10MG A205153 001 Oct 28, 2016 Feb CAHN

AB 25MG A205153 002 Oct 28, 2016 Feb CAHN

AB 50MG A205153 003 Oct 28, 2016 Feb CAHN

AB 75MG A205153 004 Oct 28, 2016 Feb CAHN

AB 100MG A205153 005 Oct 28, 2016 Feb CAHN

		TABLET;ORAL							
		DESIPRAMINE HYDROCHLORIDE							
AB		150MG		A205153	006	Oct 28, 2016	Feb	CAHN	
		<u>DESOXIMETASONE</u>							
		SPRAY;TOPICAL							
		DESOXIMETASONE							
>A>	AT	LUPIN ATLANTIS	0.25%	A208124	001	Mar 16, 2018	Mar	NEWA	
		<u>DESVENLAFAXINE SUCCINATE</u>							
		TABLET, EXTENDED RELEASE;ORAL							
		DESVENLAFAXINE SUCCINATE							
>A>	AB	CASI PHARMS INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Mar	CAHN	
>A>	AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Mar	CAHN	
>D>	AB	SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Mar	CAHN	
>D>	AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Mar	CAHN	
		<u>DEXAMETHASONE</u>							
		ELIXIR;ORAL							
		HEXADROL							
		@ ASPEN GLOBAL INC		0.5MG/5ML	N012674	001		Feb	CAHN
		SUSPENSION;INTRAOCULAR							
		DEXYCU KIT							
		+! ICON BIOSCIENCE		9%	N208912	001	Feb 09, 2018	Feb	NEWA
		TABLET;ORAL							
		DEXAMETHASONE							
BP		FERA PHARMS LLC	0.5MG	A088148	001	Apr 28, 1983	Jan	CAHN	
BP			0.75MG	A088160	001	Apr 28, 1983	Jan	CAHN	
BP			4MG	A088238	001	Apr 28, 1983	Jan	CAHN	
BP			6MG	A088481	001	Nov 28, 1983	Jan	CAHN	
		<u>DEXAMETHASONE SODIUM PHOSPHATE</u>							
		INJECTABLE;INJECTION							
		HEXADROL							
		+ @ ASPEN GLOBAL INC		EQ 4MG PHOSPHATE/ML	N014694	002		Feb	CAHN
		+ @		EQ 10MG PHOSPHATE/ML	N014694	003		Feb	CAHN
		@		EQ 20MG PHOSPHATE/ML	N014694	004		Feb	CAHN
		<u>DEXMEDETOMIDINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION							
		DEXMEDETOMIDINE HYDROCHLORIDE							
AP		ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798	001	Feb 27, 2018	Feb	NEWA	
		<u>DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE</u>							
		SYRUP;ORAL							
		PROMETH W/ DEXTROMETHORPHAN							
		@ G AND W LABS INC		15MG/5ML;6.25MG/5ML	A088762	001	Oct 31, 1984	Jan	DISC
		<u>DEXTROSE</u>							
		INJECTABLE;INJECTION							
		DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	AP	+! ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984	Mar	DISC	
>A>		+ @	50MG/ML	N019222	001	Jul 13, 1984	Mar	DISC	
AP		+!	50MG/ML	N019222	001	Jul 13, 1984	Feb	CAHN	
		DEXTROSE 70% IN PLASTIC CONTAINER							
AP		+! B BRAUN	70GM/100ML	N019626	005	Feb 18, 2015	Feb	NEWA	
		<u>DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE</u>							
		INJECTABLE;INJECTION							
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
>D>	AP	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988	Mar	CPOT	
>D>	AP		5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983	Mar	CHRS	
>A>	AP	+!	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	009	Jul 05, 1983	Mar	CHRS	
>A>	AP	+!	5GM/100ML;149MG/100ML;450MG/100ML	N018362	005	Mar 28, 1988	Mar	CPOT	
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
>D>	AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML;900MG/100ML	N019308	004	Apr 05, 1985	Mar	CTEC	
>A>			5GM/100ML;75MG/100ML;900MG/100ML	N019308	004	Apr 05, 1985	Mar	CTEC	
>D>	AP		5GM/100ML;150MG/100ML;900MG/100ML	N019308	002	Apr 05, 1985	Mar	CTEC	
>A>			5GM/100ML;150MG/100ML;900MG/100ML	N019308	002	Apr 05, 1985	Mar	CTEC	
>D>	AP	ICU MEDICAL INC	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	002	Mar 24, 1988	Mar	DISC	
>A>		+ @	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	002	Mar 24, 1988	Mar	DISC	

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988	Mar	DISC
>A>	+ @	5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988	Mar	DISC
>D>		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP	ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Mar	DISC
>A>	+ @	5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Mar	DISC
>D>		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988	Mar	DISC
>A>	+ @	5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988	Mar	DISC
>D>		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP	ICU MEDICAL INC 5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Mar	CHRS
>A>	AP	+! 5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Mar	CHRS
>D>	AP	5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Mar	DISC
>A>	+ @	5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Mar	DISC
>D>		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	BAXTER HLTHCARE 5GM/100ML;300MG/100ML;900MG/100ML	N019308	003	Apr 05, 1985	Mar	CTEC
>A>		5GM/100ML;300MG/100ML;900MG/100ML	N019308	003	Apr 05, 1985	Mar	CTEC
>D>	AP	ICU MEDICAL INC 5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988	Mar	CRLD
>A>	AP	+! 5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988	Mar	CRLD
>D>	AP	5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988	Mar	DISC
>A>	+ @	5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988	Mar	DISC
>D>		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP	ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Mar	CHRS
>A>	AP	+! 5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Mar	CHRS
>D>		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	BAXTER HLTHCARE 5GM/100ML;224MG/100ML;900MG/100ML	N019308	006	Apr 05, 1985	Mar	CTEC
>A>		5GM/100ML;224MG/100ML;900MG/100ML	N019308	006	Apr 05, 1985	Mar	CTEC
>D>	AP	ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Mar	DISC
>A>	+ @	5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Mar	DISC
>D>		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP	ICU MEDICAL INC 5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Mar	CHRS
>A>	AP	+! 5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Mar	CHRS
>D>		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	ICU MEDICAL INC 5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Mar	CRLD
>A>	AP	+! 5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Mar	CRLD
>D>		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
>D>	AP	BAXTER HLTHCARE 5GM/100ML;150MG/100ML;450MG/100ML	N018008	004		Mar	CTEC
>A>		5GM/100ML;150MG/100ML;450MG/100ML	N018008	004		Mar	CTEC
>D>	AP	ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Mar	DISC
>A>	+ @	5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Mar	DISC
>D>	AP	5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Mar	DISC
>A>	+ @	5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Mar	DISC
>D>		POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
>D>	AP	BAXTER HLTHCARE 5GM/100ML;150MG/100ML;900MG/100ML	N019308	001	Apr 05, 1985	Mar	CTEC
>A>		5GM/100ML;150MG/100ML;900MG/100ML	N019308	001	Apr 05, 1985	Mar	CTEC
>D>	AP	ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Mar	DISC
>A>	+ @	5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Mar	DISC
>D>	AP	5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Mar	DISC
>A>	+ @	5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Mar	DISC

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	+	ICU MEDICAL INC 5GM/100ML;450MG/100ML	N017607	001		Jan	CRLD

DICLOFENAC POTASSIUM

TABLET; ORAL

DICLOFENAC POTASSIUM

>A>	AB	CASI PHARMS INC 50MG	A075229	001	Nov 20, 1998	Mar	CAHN
>D>	AB	SANDOZ 50MG	A075229	001	Nov 20, 1998	Mar	CAHN

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

>A>	AB	! CASI PHARMS INC 25MG	A074376	001	Sep 28, 1995	Mar	CAHN
>A>	AB	! 50MG	A074376	002	Sep 28, 1995	Mar	CAHN
>A>	AB	! 75MG	A074394	001	Nov 30, 1995	Mar	CAHN
>D>	AB	! SANDOZ 25MG	A074376	001	Sep 28, 1995	Mar	CAHN
>D>	AB	! 50MG	A074376	002	Sep 28, 1995	Mar	CAHN
>D>	AB	! 75MG	A074394	001	Nov 30, 1995	Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

	CAPSULE;ORAL						
	BENTYL						
AB	+!	ALLERGAN SALES LLC	10MG	N007409	003	Oct 15, 1984	Jan CAHN
	INJECTABLE;INJECTION						
	BENTYL						
AP	+!	ALLERGAN SALES LLC	10MG/ML	N008370	001	Oct 15, 1984	Jan CAHN
	BENTYL PRESERVATIVE FREE						
AP	+!	ALLERGAN SALES LLC	10MG/ML	N008370	002	Oct 15, 1984	Jan CAHN
	TABLET;ORAL						
	BENTYL						
AB	+!	ALLERGAN SALES LLC	20MG	N007409	001	Oct 15, 1984	Jan CAHN

DIDANOSINE

	CAPSULE, DELAYED REL PELLETS;ORAL						
	DIDANOSINE						
>D> AB		BARR	200MG	A077167	001	Dec 03, 2004	Mar DISC
>A>	@		200MG	A077167	001	Dec 03, 2004	Mar DISC
>D> AB			250MG	A077167	002	Dec 03, 2004	Mar DISC
>A>	@		250MG	A077167	002	Dec 03, 2004	Mar DISC
>D> AB			400MG	A077167	003	Dec 03, 2004	Mar DISC
>A>	@		400MG	A077167	003	Dec 03, 2004	Mar DISC

DIPHENHYDRAMINE HYDROCHLORIDE

	CAPSULE;ORAL						
	DIPHENHYDRAMINE HYDROCHLORIDE						
	@	FOSUN PHARMA	25MG	A080832	001		Jan CAHN
	@		25MG	A080845	002		Jan CAHN
	@		50MG	A080832	002		Jan CAHN
	@		50MG	A080845	001		Jan CAHN

DOCETAXEL

	INJECTABLE;INJECTION						
	DOCETAXEL						
AP		AMNEAL PHARMS CO	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Jan NEWA
AP			80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Jan NEWA
AP			160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Jan NEWA

DOFETILIDE

	CAPSULE;ORAL						
	DOFETILIDE						
>A> AB		APICORE US	0.125MG	A208625	001	Apr 10, 2018	Mar NEWA
>A> AB			0.25MG	A208625	002	Apr 10, 2018	Mar NEWA
>A> AB			0.5MG	A208625	003	Apr 10, 2018	Mar NEWA
>A> AB		SIGMAPHARM LABS LLC	0.125MG	A207746	001	Mar 26, 2018	Mar NEWA
>A> AB			0.25MG	A207746	002	Mar 26, 2018	Mar NEWA
>A> AB			0.5MG	A207746	003	Mar 26, 2018	Mar NEWA

DONEPEZIL HYDROCHLORIDE

	TABLET;ORAL						
	DONEPEZIL HYDROCHLORIDE						
>D> AB		APOTEX	5MG	A078841	001	Jun 02, 2011	Mar DISC
>A>	@		5MG	A078841	001	Jun 02, 2011	Mar DISC
>D> AB			10MG	A078841	002	Jun 02, 2011	Mar DISC
>A>	@		10MG	A078841	002	Jun 02, 2011	Mar DISC

DOPAMINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	DOPAMINE HYDROCHLORIDE						
>A> AP		HIKMA INTL PHARMS	40MG/ML	A207707	001	Apr 11, 2018	Mar NEWA
>A> AP			80MG/ML	A207707	002	Apr 11, 2018	Mar NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

	SOLUTION/DROPS;OPHTHALMIC						
	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE						
	@	ZAMBON SPA	EQ 2% BASE;EQ 0.5% BASE	A091180	001	Dec 04, 2013	Jan DISC

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Jan	NEWA
AB		EQ 2MG BASE	A205210	002	Feb 13, 2018	Jan	NEWA
AB		EQ 4MG BASE	A205210	003	Feb 13, 2018	Jan	NEWA
AB		EQ 8MG BASE	A205210	004	Feb 13, 2018	Jan	NEWA
AB	IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Jan	CMFD
AB		EQ 2MG BASE	A075432	002	Oct 18, 2000	Jan	CMFD
AB		EQ 4MG BASE	A075432	003	Oct 18, 2000	Jan	CMFD
AB		EQ 8MG BASE	A075432	004	Oct 18, 2000	Jan	CMFD
	@ YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan	CAHN
	@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan	CAHN
	@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan	CAHN
	@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan	CAHN

DOXEPIN HYDROCHLORIDE

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

@ ACTAVIS ELIZABETH EQ 3MG BASE
 @ EQ 6MG BASE

A201951 001 Jul 26, 2013 Jan DISC
 A201951 002 Jul 26, 2013 Jan DISC

SILENOR

+ PERNIX THERAPS LLC EQ 3MG BASE
 +! EQ 6MG BASE

N022036 001 Mar 17, 2010 Jan CTEC
 N022036 002 Mar 17, 2010 Jan CTEC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

>D>	AB	CYNDEA PHARMA	3MG;0.02MG	A209423	001	Dec 22, 2017	Mar	CAHN
>A>	AB	JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Mar	CAHN
		LO-ZUMANDIMINE						
	AB	AUROBINDO PHARMA LTD	3MG;0.02MG	A209632	001	Feb 27, 2018	Feb	NEWA
		TABLET; ORAL-28						
>A>		ZUMANDIMINE						
>A>	AB	AUROBINDO PHARMA LTD	3MG;0.03MG	A209407	001	Mar 26, 2018	Mar	NEWA

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

>A>	AB	CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Mar	CAHN
>D>	AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar	CAHN

EFAVIRENZ

TABLET; ORAL

EFAVIRENZ

AB	STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018	Feb	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLA

>D>	+	GILEAD	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Mar	CAHN
>A>	+	GILEAD SCIENCES	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Mar	CAHN

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

SYMFI

>A>		SYMFI						
>A>	+	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018	Mar	NEWA
		SYMFI LO						
	+	MYLAN PHARMS INC	400MG;300MG;300MG	N208255	001	Feb 05, 2018	Feb	NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	AUROBINDO PHARMA LTD	200MG;300MG	A090513	001	Jan 26, 2018	Jan	NEWA	
>A>	AB	MYLAN PHARMS INC	200MG;300MG	A206436	001	Apr 09, 2018	Mar	NEWA

ENTECAVIRTABLET; ORAL
ENTECAVIR

>A>	AB	CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017	Mar CAHN
>A>	AB		1MG	A206672	002	May 11, 2017	Mar CAHN
>D>	AB	SANDOZ INC	0.5MG	A206672	001	May 11, 2017	Mar CAHN
>D>	AB		1MG	A206672	002	May 11, 2017	Mar CAHN

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

>A>	AT	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Mar CAHN
>D>	AT	SANDOZ INC	0.05%	A203384	001	Dec 07, 2016	Mar CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>D>	AP	EASTMAN KODAK	0.01MG/ML; 2%	A040057	002	Feb 26, 1993	Mar DISC
>A>		@	0.01MG/ML; 2%	A040057	002	Feb 26, 1993	Mar DISC
>D>	AP		0.02MG/ML; 2%	A040057	001	Feb 26, 1993	Mar DISC
>A>		@	0.02MG/ML; 2%	A040057	001	Feb 26, 1993	Mar DISC

EPROSARTAN MESYLATETABLET; ORAL
EPROSARTAN MESYLATE

>D>	AB	MYLAN PHARMS INC	EQ 600MG BASE	A202012	002	Nov 16, 2011	Mar CHRS
>A>	AB	!	EQ 600MG BASE	A202012	002	Nov 16, 2011	Mar CHRS
>D>		TEVETEN					
>D>	AB	+ ABBVIE	EQ 400MG BASE	N020738	005	Dec 22, 1997	Mar DISC
>A>		+ @	EQ 400MG BASE	N020738	005	Dec 22, 1997	Mar DISC
>D>	AB	+!	EQ 600MG BASE	N020738	006	May 27, 1999	Mar DISC
>A>		+ @	EQ 600MG BASE	N020738	006	May 27, 1999	Mar DISC

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

AP		SAGENT PHARMS	2MG/ML	A204693	001	Mar 07, 2018	Feb NEWA
AP			75MG/100ML	A204693	002	Mar 07, 2018	Feb NEWA

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATETABLET; ORAL
STEGLUJAN

+		MERCK SHARP DOHME	5MG; EQ 100MG BASE	N209805	001	Dec 19, 2017	Jan CMS1
+		!	15MG; EQ 100MG BASE	N209805	002	Dec 19, 2017	Jan CMS1

ERYTHROMYCINTABLET; ORAL
ERYTHROMYCIN

AB		AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Feb NEWA
AB			500MG	A209720	002	Mar 09, 2018	Feb NEWA
AB		ARBOR PHARMS LLC	250MG	A061621	001		Feb CTEC
AB		!	500MG	A061621	002		Feb CTEC

ESCITALOPRAM OXALATESOLUTION; ORAL
LEXAPRO

AA	+	ALLERGAN SALES LLC	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan CAHN
----	---	--------------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL
LEXAPRO

AB	+	ALLERGAN SALES LLC	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan CAHN
AB	+		EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan CAHN
AB	+	!	EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan CAHN

ESTRADIOLCREAM; VAGINAL
ESTRADIOL

AB		ALVOGEN PINE BROOK	0.01%	A209767	001	Mar 05, 2018	Feb NEWA
AB		PERRIGO UK FINCO	0.01%	A210194	001	Jan 22, 2018	Jan NEWA
>A>	AB	TEVA PHARMS USA	0.01%	A210488	001	Mar 30, 2018	Mar NEWA

ESTRADIOL VALERATEINJECTABLE; INJECTION
ESTRADIOL VALERATE

@	FOSUN PHARMA	10MG/ML	A040628	001	Oct 04, 2007	Jan	CAHN
@		20MG/ML	A040628	002	Oct 04, 2007	Jan	CAHN
@		40MG/ML	A040628	003	Oct 04, 2007	Jan	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Feb	NEWA
----	-----------------	-----------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

BALCOLTRA

AVION PHARMS 0.02MG;0.1MG

N208612 001 Jan 09, 2018 Feb CAHN

NEUVOSYN LABS LLC 0.02MG;0.1MG

N208612 001 Jan 09, 2018 Jan NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A> AB	MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	Mar	NEWA
--------	----------------	---	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

MODICON 28

+ @ JANSSEN PHARMS 0.035MG;0.5MG

N017735 001

Feb DISC

WERA

AB	! NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Feb	CHRS
----	-------------------	---------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>A> AB	APOTEX INC	0.02MG;1MG	A208639	001	Mar 21, 2018	Mar	NEWA
--------	------------	------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE, TABLET; ORAL

LO MINASTRIN FE

+ @ APIL 0.01MG,0.01MG,N/A;1MG,N/A,N/A

N204654 001 Jul 24, 2013 Jan DISC

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

@ PLD ACQUISITIONS 20MG

A075302 001 Apr 16, 2001 Feb CAHN

@ 40MG

A075302 002 Apr 16, 2001 Feb CAHN

FENOFIBRATE

TABLET; ORAL

FENOFIBRATE

AB	AMNEAL PHARMS LLC	48MG	A209951	001	Feb 09, 2018	Jan	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

>A> AB		54MG	A209950	001	Mar 19, 2018	Mar	NEWA
--------	--	------	---------	-----	--------------	-----	------

AB		145MG	A209951	002	Feb 09, 2018	Jan	NEWA
----	--	-------	---------	-----	--------------	-----	------

>A> AB		160MG	A209950	002	Mar 19, 2018	Mar	NEWA
--------	--	-------	---------	-----	--------------	-----	------

FENTANYLFILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC-37

+ JANSSEN PHARMS 37.5MCG/HR

N019813 006 Jan 24, 2018 Jan NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	! INFORLIFE	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Jan	CAHN
----	-------------	----------------------	---------	-----	--------------	-----	------

AP	!	400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Jan	CAHN
----	---	----------------------	---------	-----	--------------	-----	------

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

@ G AND W LABS 0.025%

A089525 001 Jul 26, 1988 Jan DISC

OIL/DROPS; OTIC

>A> FLAC

>A> AT	PATRIN PHARMA INC	0.01%	A210736	001	Apr 11, 2018	Mar	NEWA
--------	-------------------	-------	---------	-----	--------------	-----	------

		SOLUTION;TOPICAL FLUOCINOLONE ACETONIDE @ G AND W LABS INC	0.01%	A207441	001	Sep 28, 2016	Jan DISC
<u>FLUORESCEIN SODIUM</u>							
		INJECTABLE;INTRAVENOUS FLUORESCITE					
AP	+	ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N021980	001	Mar 28, 2006	Feb CAHN
<u>FLUOXETINE HYDROCHLORIDE</u>							
		TABLET;ORAL FLUOXETINE HYDROCHLORIDE @ FOSUN PHARMA	EQ 10MG BASE	A076024	001	Jan 29, 2002	Jan CAHN
<u>FLUTAMIDE</u>							
		CAPSULE;ORAL FLUTAMIDE @ YAOPHARMA CO LTD	125MG	A075818	001	Sep 18, 2001	Jan CAHN
<u>FLUTICASONE PROPIONATE</u>							
		SPRAY, METERED;NASAL XHANCE +! OPTINOSE US INC	0.093MG	N209022	001	Sep 18, 2017	Jan CMS1
<u>FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE</u>							
		TABLET;ORAL FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE					
AB		EMCURE PHARMS LTD	10MG;12.5MG	A079025	001	Sep 17, 2010	Jan CAHN
AB	!		20MG;12.5MG	A079025	002	Sep 17, 2010	Jan CAHN
<u>GEMCITABINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION GEMCITABINE HYDROCHLORIDE					
>D>	AP	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012	Mar DISC
>A>		@	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012	Mar DISC
>D>	AP		EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012	Mar DISC
>A>		@	EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012	Mar DISC
<u>GEMFIBROZIL</u>							
		TABLET;ORAL GEMFIBROZIL @ YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995	Jan CAHN
<u>GENTAMICIN SULFATE</u>							
		OINTMENT;TOPICAL GENTAMICIN SULFATE G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	Jan CMFD
<u>GLATIRAMER ACETATE</u>							
		INJECTABLE;SUBCUTANEOUS GLATOPIA SANDOZ INC	40MG/ML	A206921	001	Feb 12, 2018	Jan NEWA
<u>GLYBURIDE</u>							
		TABLET;ORAL GLYBURIDE (MICRONIZED) @ YAOPHARMA CO LTD	1.5MG	A075174	001	Jun 22, 1998	Jan CAHN
		@	3MG	A075174	002	Jun 22, 1998	Jan CAHN
<u>GLYCINE</u>							
		SOLUTION;IRRIGATION AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER					
>D>	AT	BAXTER HLTHCARE	1.5GM/100ML	N017865	001		Mar CRLD
>A>	AT	+	1.5GM/100ML	N017865	001		Mar CRLD

GRANISETRON HYDROCHLORIDEINJECTABLE; INJECTION
GRANISETRON HYDROCHLORIDE

@ TEVA PHARMS USA EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A 077963 001 Jan 03, 2008 Feb DISC

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

>A> AB CHARTWELL MOLECULAR EQ 1MG BASE A 078037 001 Feb 27, 2008 Mar CAHN

>D> AB CIPLA LTD EQ 1MG BASE A 078037 001 Feb 27, 2008 Mar CAHN

GRISEOFULVIN, ULTRAMICROSIZED

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZED

AB MOUNTAIN 125MG A 204371 001 Jan 09, 2014 Jan CAHN

AB 250MG A 204371 002 Jan 09, 2014 Jan CAHN

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

@ YAOPHARMA CO LTD EQ 4MG BASE A 074517 001 Sep 30, 1998 Jan CAHN

@ EQ 8MG BASE A 074517 002 Sep 30, 1998 Jan CAHN

HALCINONIDE

CREAM; TOPICAL

HALOG

+! SUN PHARM INDS INC 0.1% N 017556 001

Feb CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

ULTRAVATE

AB + SUN PHARM INDS INC 0.05% N 019967 001 Dec 27, 1990 Feb CAHN

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

>A> AB TELIGENT PHARMA INC 0.05% A 209978 001 Mar 20, 2018 Mar NEWA

ULTRAVATE

AB + SUN PHARM INDS INC 0.05% N 019968 001 Dec 17, 1990 Feb CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

@ FOSUN PHARMA EQ 5MG BASE/ML A 076464 001 Sep 29, 2004 Jan CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

>A> AP CASI PHARMS INC 5,000 UNITS/ML A 091659 001 Jun 08, 2011 Mar CAHN

>D> AP SANDOZ 5,000 UNITS/ML A 091659 001 Jun 08, 2011 Mar CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

AA SCIEGEN PHARMS INC 10MG A 205236 001 May 26, 2017 Feb CAHN

AA 25MG A 205236 002 May 26, 2017 Feb CAHN

AA 50MG A 205236 003 May 26, 2017 Feb CAHN

AA 100MG A 205236 004 May 26, 2017 Feb CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

>D> AB APOTEX 12.5MG A 078389 001 May 16, 2008 Mar DISC

>A> @ 12.5MG A 078389 001 May 16, 2008 Mar DISC

TABLET; ORAL

HYDROCHLOROTHIAZIDE

>D> AB APOTEX 25MG A 040774 001 Oct 03, 2007 Mar DISC

>A> @ 25MG A 040774 001 Oct 03, 2007 Mar DISC

>D> AB 50MG A 040774 002 Oct 03, 2007 Mar DISC

>A> @ 50MG A 040774 002 Oct 03, 2007 Mar DISC

AB SCIEGEN PHARMS INC 25MG A 203018 001 Jul 23, 2014 Jan CAHN

AB 50MG A 203018 002 Jul 23, 2014 Jan CAHN

@ YAOPHARMA CO LTD 25MG A 087565 001 Mar 09, 1982 Jan CAHN

@ 50MG A 084912 001 Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

>D>	AB	APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010	Mar	DISC
>A>		@	12.5MG;50MG	A090150	001	Oct 06, 2010	Mar	DISC
>D>	AB		12.5MG;100MG	A090150	002	Aug 11, 2010	Mar	DISC
>A>		@	12.5MG;100MG	A090150	002	Aug 11, 2010	Mar	DISC
>D>	AB		25MG;100MG	A090150	003	Oct 06, 2010	Mar	DISC
>A>		@	25MG;100MG	A090150	003	Oct 06, 2010	Mar	DISC

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

		@ YAOPHARMA CO LTD	15MG;250MG	A070182	001	Jan 15, 1986	Jan	CAHN
		@	25MG;250MG	A070183	001	Jan 15, 1986	Jan	CAHN
		@	30MG;500MG	A070543	001	Jan 15, 1986	Jan	CAHN
		@	50MG;500MG	A070544	001	Jan 15, 1986	Jan	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@ YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987	Jan	CAHN
		@	25MG;80MG	A071061	001	Aug 26, 1987	Jan	CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

		@ YAOPHARMA CO LTD	25MG;25MG	A086881	001		Jan	CAHN
--	--	--------------------	-----------	---------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A>	AB	!	CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Mar	CAHN
>D>	AB	!	SANDOZ	25MG;50MG	A073191	001	Jul 31, 1991	Mar	CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB		APOTEX INC	12.5MG;80MG	A203026	001	Mar 21, 2013	Mar	DISC
>A>		@		12.5MG;80MG	A203026	001	Mar 21, 2013	Mar	DISC
>D>	AB			12.5MG;160MG	A203026	002	Mar 21, 2013	Mar	DISC
>A>		@		12.5MG;160MG	A203026	002	Mar 21, 2013	Mar	DISC
>D>	AB			12.5MG;320MG	A203026	003	Mar 21, 2013	Mar	DISC
>A>		@		12.5MG;320MG	A203026	003	Mar 21, 2013	Mar	DISC
>D>	AB			25MG;160MG	A203026	004	Mar 21, 2013	Mar	DISC
>A>		@		25MG;160MG	A203026	004	Mar 21, 2013	Mar	DISC
>D>	AB			25MG;320MG	A203026	005	Mar 21, 2013	Mar	DISC
>A>		@		25MG;320MG	A203026	005	Mar 21, 2013	Mar	DISC

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

VANTRELA ER

		+ @	TEVA BRANDED PHARM	15MG	N207975	001	Jan 17, 2017	Jan	DISC
		+ @		30MG	N207975	002	Jan 17, 2017	Jan	DISC
		+ @		45MG	N207975	003	Jan 17, 2017	Jan	DISC
		+ @		60MG	N207975	004	Jan 17, 2017	Jan	DISC
		+ @		90MG	N207975	005	Jan 17, 2017	Jan	DISC

HYDROCORTISONE VALERATE

CREAM; TOPICAL

WESTCORT

>D>		+ @	RANBAXY LABS LTD	0.2%	N017950	001		Mar	CAHN
>A>		+ @	SUN PHARM INDS INC	0.2%	N017950	001		Mar	CAHN

OINTMENT; TOPICAL

WESTCORT

		+ @	SUN PHARM INDS INC	0.2%	N018726	001	Aug 08, 1983	Feb	CAHN
--	--	-----	--------------------	------	---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

	TABLET; ORAL						
	HYDROMORPHONE HYDROCHLORIDE						
AB	ASCENT PHARMS INC	2MG	A210506	001	Jan 17, 2018	Jan	NEWA
AB		4MG	A210506	002	Jan 17, 2018	Jan	NEWA
AB		8MG	A210506	003	Jan 17, 2018	Jan	NEWA

HYDROXYPROGESTERONE CAPROATE

	SOLUTION; SUBCUTANEOUS						
	MAKENA (AUTOINJECTOR)						
+!	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Feb	NEWA

HYDROXYZINE HYDROCHLORIDE

	TABLET; ORAL						
	ATARAX						
+ @	PFIZER	10MG	N010392	001		Feb	CRLD
+ @		25MG	N010392	004		Feb	CRLD
+ @		50MG	N010392	006		Feb	CRLD
+ @		100MG	N010392	005		Feb	CRLD

IBRUTINIB

	TABLET; ORAL						
	IMBRUVICA						
+	PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018	Feb	NEWA
+		280MG	N210563	002	Feb 16, 2018	Feb	NEWA
+		420MG	N210563	003	Feb 16, 2018	Feb	NEWA
+!		560MG	N210563	004	Feb 16, 2018	Feb	NEWA

IBUPROFEN

	SUSPENSION; ORAL						
	IBUPROFEN						
	AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	Feb	NEWA

IBUTILIDE FUMARATE

	INJECTABLE; INJECTION						
	IBUTILIDE FUMARATE						
@	MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010	Jan	DISC

IMIQUIMOD

	CREAM; TOPICAL						
	IMIQUIMOD						
@	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Jan	DISC

INDAPAMIDE

	TABLET; ORAL						
	INDAPAMIDE						
@	YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996	Jan	CAHN
@		2.5MG	A074594	002	May 23, 1996	Jan	CAHN

INSULIN GLARGINE RECOMBINANT

	SOLUTION; SUBCUTANEOUS							
	TOUJEO MAX SOLOSTAR							
>A>	+!	SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N206538	002	Mar 26, 2018	Mar	NEWA
		TOUJEO SOLOSTAR						
>D>	+!	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Mar	CPOT
>A>	+!		450 UNITS/1.5ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Mar	CPOT

IPRATROPIUM BROMIDE

	SPRAY, METERED; NASAL							
	ATROVENT							
+ @	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995	Jan	DISC	
+ @		0.042MG/SPRAY	N020394	001	Oct 20, 1995	Jan	DISC	
	IPRATROPIUM BROMIDE							
AB	!	WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Jan	CHRS
AB	!		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Jan	CHRS

IRBESARTANTABLET; ORAL
IRBESARTAN

>D>	AB	APOTEX INC	75MG	A200832	001	Oct 15, 2012	Mar	DISC
>A>		@	75MG	A200832	001	Oct 15, 2012	Mar	DISC
>D>	AB		150MG	A200832	002	Oct 15, 2012	Mar	DISC
>A>		@	150MG	A200832	002	Oct 15, 2012	Mar	DISC
>D>	AB		300MG	A200832	003	Oct 15, 2012	Mar	DISC
>A>		@	300MG	A200832	003	Oct 15, 2012	Mar	DISC

IVACAFTOR; IVACAFTOR, TEZACAFTORTABLET, TABLET; ORAL
SYMDEKO (COPACKAGED)

+!	VERTEX PHARMS INC	150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018	Feb	NEWA
----	-------------------	------------------------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINESOLUTION/DROPS; OPHTHALMIC
KETOROLAC TROMETHAMINE

AT	SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	Jan	CAHN
----	------------	------	---------	-----	--------------	-----	------

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
CIMDUO

+!	MYLAN LABS LTD	300MG;300MG	N022141	001	Feb 28, 2018	Feb	NEWA
----	----------------	-------------	---------	-----	--------------	-----	------

LAMIVUDINE; ZIDOVUDINETABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

>A>	AB	SHANGHAI DESANO	150MG;300MG	A206375	001	Apr 10, 2018	Mar	NEWA
-----	----	-----------------	-------------	---------	-----	--------------	-----	------

LEFLUNOMIDETABLET; ORAL
LEFLUNOMIDE

@	FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jan	CAHN
@		20MG	A077087	002	Sep 13, 2005	Jan	CAHN

LEUCOVORIN CALCIUMINJECTABLE; INJECTION
LEUCOVORIN CALCIUM

>A>	FRESENIUS KABI USA	EQ 10MG BASE/ML	A207241	001	Mar 14, 2018	Mar	NEWA
-----	--------------------	-----------------	---------	-----	--------------	-----	------

LEUPROLIDE ACETATEINJECTABLE; INJECTION
LUPRON

+ @	ABBVIE ENDOCRINE INC	1MG/0.2ML	N019010	001	Apr 09, 1985	Feb	CRLD
-----	----------------------	-----------	---------	-----	--------------	-----	------

LEVETIRACETAMINJECTABLE; IV (INFUSION)
LEVETIRACETAM

>A>	AP	HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018	Mar	NEWA
-----	----	-------------------	----------------------	---------	-----	--------------	-----	------

TABLET; ORAL
LEVETIRACETAM

@	FOSUN PHARMA	250MG	A077324	001	Jan 15, 2009	Jan	CAHN
@		500MG	A077324	002	Jan 15, 2009	Jan	CAHN
@		750MG	A077324	003	Jan 15, 2009	Jan	CAHN
@		1GM	A077324	004	Jan 15, 2009	Jan	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDETABLET; ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

@	FOSUN PHARMA	5MG	A090486	001	Mar 26, 2013	Jan	CAHN
---	--------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACININJECTABLE; INJECTION
LEVAQUIN

+ @	JANSSEN PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Feb	DISC
+ @		EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Feb	DISC

LEVOFLOXACIN

>D>	AP	AUROBINDO PHARMA LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Mar	CHRS
>A>	AP	!	EQ 500MG/20ML (EQ 25MG/ML)	A202328	001	Jan 24, 2013	Mar	CHRS
>D>	AP		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Mar	CHRS

INJECTABLE; INJECTION

LEVOFLOXACIN

>A>	AP	!		EQ 750MG/30ML (EQ 25MG/ML)	A202328	002	Jan 24, 2013	Mar	CHRS
>D>	AP		EMCURE PHARMS LTD	EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Mar	DISC
>A>		@		EQ 500MG/20ML (EQ 25MG/ML)	A202590	001	Jan 24, 2013	Mar	DISC
>D>	AP			EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Mar	DISC
>A>		@		EQ 750MG/30ML (EQ 25MG/ML)	A202590	002	Jan 24, 2013	Mar	DISC
		@	ZYDUS PHARMS USA INC	EQ 500MG/20ML (EQ 25MG/ML)	A205968	001	Jun 01, 2017	Feb	DISC
		@		EQ 750MG/30ML (EQ 25MG/ML)	A205968	002	Jun 01, 2017	Feb	DISC
			LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	!		INFORLIFE	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jan	CAHN
AP	!			EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jan	CAHN
AP	!			EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jan	CAHN

TABLET; ORAL

LEVAQUIN

	+	@	JANSSEN PHARMS	250MG	N020634	001	Dec 20, 1996	Feb	DISC
	+	@		500MG	N020634	002	Dec 20, 1996	Feb	DISC
	+	@		750MG	N020634	003	Sep 08, 2000	Feb	DISC
			LEVOFLOXACIN						
AB	!		AUROBINDO PHARMA LTD	750MG	A201043	003	Jun 20, 2011	Feb	CHRS

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

	+		ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan	CAHN
	+			EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan	CAHN
	+			EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan	CAHN
	+	!		EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan	CAHN

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

AP			PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jan	CAHN
AP				500MCG/VIAL	A206163	002	Jun 29, 2016	Jan	CAHN

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT			TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Jan	NEWA
			PATCH; TOPICAL						
			ZTLIDO						
	+	!	SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018	Feb	NEWA

LINACLOTIDE

CAPSULE; ORAL

LINZESS

	+		ALLERGAN SALES LLC	72MCG	N202811	003	Jan 25, 2017	Jan	CAHN
	+			145MCG	N202811	001	Aug 30, 2012	Jan	CAHN
	+	!		290MCG	N202811	002	Aug 30, 2012	Jan	CAHN

LISINAPRIL

TABLET; ORAL

LISINAPRIL

>A>	AB		CASI PHARMS INC	2.5MG	A075994	001	Jul 01, 2002	Mar	CAHN
>A>	AB			5MG	A075994	002	Jul 01, 2002	Mar	CAHN
>A>	AB			10MG	A075994	003	Jul 01, 2002	Mar	CAHN
>A>	AB			20MG	A075994	004	Jul 01, 2002	Mar	CAHN
>A>	AB			30MG	A075994	005	Jul 01, 2002	Mar	CAHN
>A>	AB			40MG	A075994	006	Jul 01, 2002	Mar	CAHN
>D>	AB		SANDOZ	2.5MG	A075994	001	Jul 01, 2002	Mar	CAHN
>D>	AB			5MG	A075994	002	Jul 01, 2002	Mar	CAHN
>D>	AB			10MG	A075994	003	Jul 01, 2002	Mar	CAHN
>D>	AB			20MG	A075994	004	Jul 01, 2002	Mar	CAHN
>D>	AB			30MG	A075994	005	Jul 01, 2002	Mar	CAHN
>D>	AB			40MG	A075994	006	Jul 01, 2002	Mar	CAHN

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

		@	YAOPHARMA CO LTD	2MG	A072993	001	Aug 28, 1992	Jan	CAHN
--	--	---	------------------	-----	---------	-----	--------------	-----	------

LORAZEPAMTABLET; ORAL
LORAZEPAM

@	MYLAN	0.5MG	A071591	002	Oct 13, 1987	Jan	CMS1
@		1MG	A071591	003	Oct 13, 1987	Jan	CMS1

LOSARTAN POTASSIUMTABLET; ORAL
LOSARTAN POTASSIUM

>D>	AB	APOTEX CORP	25MG	A090790	001	Oct 06, 2010	Mar	DISC
>A>		@	25MG	A090790	001	Oct 06, 2010	Mar	DISC
>D>	AB		50MG	A090790	002	Oct 06, 2010	Mar	DISC
>A>		@	50MG	A090790	002	Oct 06, 2010	Mar	DISC
>D>	AB		100MG	A090790	003	Oct 06, 2010	Mar	DISC
>A>		@	100MG	A090790	003	Oct 06, 2010	Mar	DISC

LUTETIUM DOTATATE LU-177SOLUTION; IV (INFUSION)
LUTATHERA

+	!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jan	NEWA
---	---	-------------	----------	---------	-----	--------------	-----	------

MACIMORELIN ACETATEFOR SOLUTION; ORAL
MACRILEN

+	!	STRONGBRIDGE IRELAND	EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Jan	CAHN
---	---	----------------------	--------------------	---------	-----	--------------	-----	------

MANGANESE CHLORIDEINJECTABLE; INJECTION
MANGANESE CHLORIDE IN PLASTIC CONTAINER

>D>		HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Mar	CRLD
>A>		+	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Mar	CRLD

MANNITOL; SORBITOLSOLUTION; IRRIGATION
SORBITOL-MANNITOL IN PLASTIC CONTAINER

>D>		ICU MEDICAL INC	540MG/100ML; 2.7GM/100ML	N018316	001		Mar	CRLD
>A>		+	540MG/100ML; 2.7GM/100ML	N018316	001		Mar	CRLD

MEBENDAZOLETABLET, CHEWABLE; ORAL
VERMOX

+	@	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Feb	DISC
---	---	----------------	-------	---------	-----	--------------	-----	------

MECLOFENAMATE SODIUMCAPSULE; ORAL
MECLOFENAMATE SODIUM

@	FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan	CAHN
@		EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan	CAHN

MEFENAMIC ACIDCAPSULE; ORAL
MEFENAMIC ACID

AB		MICRO LABS	250MG	A090562	001	Nov 19, 2010	Feb	CAHN
----	--	------------	-------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDESOLUTION; ORAL
MEMANTINE HYDROCHLORIDE

AA		APOTEX INC	2MG/ML	A209955	001	Feb 09, 2018	Jan	NEWA
AA		+	NAMENDA	N021627	001	Apr 18, 2005	Jan	CAHN
AB		+	ALLERGAN SALES LLC	N021487	001	Oct 16, 2003	Jan	CAHN
AB		+	NAMENDA	N021487	002	Oct 16, 2003	Jan	CAHN

MEROPENEM; VABORBACTAMPOWDER; IV (INFUSION)
VABOMERE

+! REMPEX PHARMS 1GM/VIAL;1GM/VIAL N209776 001 Aug 29, 2017 Jan CAHN

MESALAMINEENEMA; RECTAL
MESALAMINE

@ G AND W LABS INC 4GM/60ML A076841 001 Sep 30, 2004 Jan DISC

SUPPOSITORY; RECTAL
CANASA

@ ALLERGAN SALES LLC 500MG N021252 001 Jan 05, 2001 Jan CAHN

AB +! 1GM N021252 002 Nov 05, 2004 Jan CAHN

TABLET, DELAYED RELEASE; ORAL
MESALAMINE

>A> AB ACTAVIS LABS FL 1.2GM A203817 001 Mar 23, 2018 Mar NEWA

MESNAINJECTABLE; INTRAVENOUS
MESNA

@ MYLAN INSTITUTIONAL 100MG/ML A076488 001 Mar 08, 2012 Jan DISC

METARAMINOL BITARTRATEINJECTABLE; INJECTION
METARAMINOL BITARTRATE

@ FRESENIUS KABI USA EQ 10MG BASE/ML A080722 001 Feb DISC

METAXALONETABLET; ORAL
METAXALONE

MOUNTAIN 400MG A040486 001 Feb 27, 2015 Jan CAHN

@ PRIMUS PHARMS 640MG N022503 001 Jun 01, 2015 Jan CAHN

METFORMIN HYDROCHLORIDETABLET; ORAL
METFORMIN HYDROCHLORIDE

>D> AB SANDOZ 500MG A075985 001 Jan 25, 2002 Mar DISC

>A> @ 500MG A075985 001 Jan 25, 2002 Mar DISC

>D> AB 850MG A075985 002 Jan 25, 2002 Mar DISC

>A> @ 850MG A075985 002 Jan 25, 2002 Mar DISC

>D> AB 1GM A075985 003 Jan 25, 2002 Mar DISC

>A> @ 1GM A075985 003 Jan 25, 2002 Mar DISC

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

>A> AB1 ALIGNSCIENCE PHARMA 500MG A209303 001 Mar 19, 2018 Mar NEWA

>A> AB1 GRANULES INDIA LTD 500MG A209313 001 Mar 16, 2018 Mar NEWA

>A> AB 750MG A209313 002 Mar 16, 2018 Mar NEWA

METHADONE HYDROCHLORIDETABLET; ORAL
METHADONE HYDROCHLORIDE

>A> AA SUN PHARM INDUSTRIES 5MG A208305 001 Mar 30, 2018 Mar NEWA

>A> AA 10MG A208305 002 Mar 30, 2018 Mar NEWA

METHIMAZOLETABLET; ORAL
METHIMAZOLE

>A> AB CASI PHARMS INC 5MG A040411 001 Mar 27, 2001 Mar CAHN

>A> AB 10MG A040411 002 Mar 27, 2001 Mar CAHN

>D> AB SANDOZ 5MG A040411 001 Mar 27, 2001 Mar CAHN

>D> AB 10MG A040411 002 Mar 27, 2001 Mar CAHN

METHOCARBAMOLTABLET; ORAL
METHOCARBAMOL

AA ALLIED PHARMA INC 500MG A203550 001 Feb 08, 2017 Feb CAHN

AA 750MG A203550 002 Feb 08, 2017 Feb CAHN

@ FOSUN PHARMA 500MG A084616 001 Jan CAHN

@ 750MG A084615 001 Jan CAHN

METHYLCLOTHIAZIDE

TABLET;ORAL

METHYLCLOTHIAZIDE

@ YAOPHARMA CO LTD	2.5MG	A 089835	001	Aug 18, 1988	Jan CAHN
@	5MG	A 089837	001	Aug 18, 1988	Jan CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@ YAOPHARMA CO LTD	125MG	A 071700	001	Mar 02, 1988	Jan CAHN
@	250MG	N 018934	001	Jun 29, 1984	Jan CAHN
@	500MG	N 018934	002	Jun 29, 1984	Jan CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METADATE CD

>A>	AB2	+	LANNETT CO INC	10MG	N 021259	003	May 27, 2003	Mar CAHN
>A>	AB2	+		20MG	N 021259	001	Apr 03, 2001	Mar CAHN
>A>	AB2	+		30MG	N 021259	002	Jun 19, 2003	Mar CAHN
>A>	AB2	+		40MG	N 021259	004	Feb 19, 2006	Mar CAHN
>A>	AB2	+		50MG	N 021259	005	Feb 19, 2006	Mar CAHN
>A>	AB2	+	!	60MG	N 021259	006	Feb 19, 2006	Mar CAHN
>D>	AB2	+	UCB INC	10MG	N 021259	003	May 27, 2003	Mar CAHN
>D>	AB2	+		20MG	N 021259	001	Apr 03, 2001	Mar CAHN
>D>	AB2	+		30MG	N 021259	002	Jun 19, 2003	Mar CAHN
>D>	AB2	+		40MG	N 021259	004	Feb 19, 2006	Mar CAHN
>D>	AB2	+		50MG	N 021259	005	Feb 19, 2006	Mar CAHN
>D>	AB2	+	!	60MG	N 021259	006	Feb 19, 2006	Mar CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB1	MAYNE PHARMA	10MG	A 200886	001	Feb 26, 2018	Feb NEWA
-----	--------------	------	----------	-----	--------------	----------

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	BIONPHARMA INC	5MG	A 209753	001	Mar 02, 2018	Feb NEWA
AB		10MG	A 209753	002	Mar 02, 2018	Feb NEWA
AB		20MG	A 209753	003	Mar 02, 2018	Feb NEWA
>A>	AB	LANNETT CO INC	A 086429	001		Mar CAHN
>A>	AB		A 085799	001		Mar CAHN
>A>	AB		A 086428	001		Mar CAHN
AB	MOUNTAIN	5MG	A 091159	001	Mar 12, 2014	Jan CAHN
AB		10MG	A 091159	002	Mar 12, 2014	Jan CAHN
AB		20MG	A 091159	003	Mar 12, 2014	Jan CAHN
>D>	AB	UCB INC	A 086429	001		Mar CAHN
>D>	AB		A 085799	001		Mar CAHN
>D>	AB		A 086428	001		Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

>A>	@	LANNETT CO INC	10MG	A 040306	001	Oct 20, 1999	Mar CAHN
>A>	AB	!	20MG	A 089601	001	Jun 01, 1988	Mar CAHN
>D>	@	UCB INC	10MG	A 040306	001	Oct 20, 1999	Mar CAHN
>D>	AB	!	20MG	A 089601	001	Jun 01, 1988	Mar CAHN

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ACTAVIS LABS FL	54MG	A 076655	001	Mar 21, 2018	Mar NEWA
AB	AMNEAL PHARMS	18MG	A 207515	001	Feb 01, 2018	Jan NEWA	
AB		27MG	A 207515	002	Feb 01, 2018	Jan NEWA	
AB		36MG	A 207515	003	Feb 01, 2018	Jan NEWA	
AB		54MG	A 207515	004	Feb 01, 2018	Jan NEWA	
AB	MOUNTAIN	18MG	A 208607	001	Jul 14, 2017	Jan CAHN	
AB		27MG	A 208607	002	Jul 14, 2017	Jan CAHN	
AB		36MG	A 208607	003	Jul 14, 2017	Jan CAHN	
AB		54MG	A 208607	004	Jul 14, 2017	Jan CAHN	
!	OSMOTICA	72MG	A 205327	005	Jul 28, 2017	Jan CHRS	

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@ YAOPHARMA CO LTD	EQ 5MG BASE	A 074478	001	Oct 05, 1995	Jan CAHN
@	EQ 10MG BASE	A 072215	001	Jan 30, 1990	Jan CAHN
@	EQ 10MG BASE	A 074478	002	Oct 05, 1995	Jan CAHN

METOLAZONE

TABLET;ORAL

ZAROXOLYN

>A>	AB	+	LANNETT CO INC	2.5MG	N017386	001		Mar	CAHN
>A>	AB	+	!	5MG	N017386	002		Mar	CAHN
>A>	AB	+	!	10MG	N017386	003		Mar	CAHN
>D>	AB	+	UCB INC	2.5MG	N017386	001		Mar	CAHN
>D>	AB	+	!	5MG	N017386	002		Mar	CAHN
>D>	AB	+	!	10MG	N017386	003		Mar	CAHN

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jan	NEWA
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jan	NEWA
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jan	NEWA
+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

>A>	AB		ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Mar	CMS1
	AB		NOVAST LABS LTD	EQ 25MG TARTRATE	A204106	001	Feb 06, 2018	Jan	NEWA
	AB			EQ 50MG TARTRATE	A204106	002	Feb 06, 2018	Jan	NEWA
	AB			EQ 100MG TARTRATE	A204106	003	Feb 06, 2018	Jan	NEWA
	AB			EQ 200MG TARTRATE	A204106	004	Feb 06, 2018	Jan	NEWA
>A>	AB		ZYDUS PHARMS USA INC	EQ 25MG TARTRATE	A203894	001	Mar 23, 2018	Mar	NEWA
>A>	AB			EQ 50MG TARTRATE	A203894	002	Mar 23, 2018	Mar	NEWA
>A>	AB			EQ 100MG TARTRATE	A203894	003	Mar 23, 2018	Mar	NEWA
>A>	AB			EQ 200MG TARTRATE	A203894	004	Mar 23, 2018	Mar	NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

@	RENATA	50MG	A074453	001	Apr 27, 1995	Jan	CAHN
@		100MG	A074453	002	Apr 27, 1995	Jan	CAHN
@	YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994	Jan	CAHN
@		100MG	A073289	001	Mar 25, 1994	Jan	CAHN

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

@	FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982	Jan	CAHN
@		250MG	N018740	001	Oct 22, 1982	Jan	CAHN
@		500MG	N018620	002	Jun 02, 1983	Jan	CAHN
@		500MG	N018740	002	Oct 22, 1982	Jan	CAHN

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB			APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Feb	CTEC
AB				5MG	A077746	002	Sep 12, 2006	Feb	CTEC
AB				10MG	A077746	003	Sep 12, 2006	Feb	CTEC
>A>	AB		CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	Mar	CAHN
>A>	AB			5MG	A076514	002	Sep 11, 2003	Mar	CAHN
>A>	AB			10MG	A076514	003	Jul 02, 2004	Mar	CAHN
>D>	AB		SANDOZ	2.5MG	A076514	001	Sep 11, 2003	Mar	CAHN
>D>	AB			5MG	A076514	002	Sep 11, 2003	Mar	CAHN
>D>	AB			10MG	A076514	003	Jul 02, 2004	Mar	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

>A>		@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Mar	CAHN
>A>		@		25MG	A205071	002	Jan 27, 2016	Mar	CAHN
>A>		@		50MG	A205071	003	Jan 27, 2016	Mar	CAHN
>A>		@		100MG	A205071	004	Jan 27, 2016	Mar	CAHN
>D>		@	WINDLAS HLTHCARE	12.5MG	A205071	001	Jan 27, 2016	Mar	CAHN
>D>		@		25MG	A205071	002	Jan 27, 2016	Mar	CAHN
>D>		@		50MG	A205071	003	Jan 27, 2016	Mar	CAHN
>D>		@		100MG	A205071	004	Jan 27, 2016	Mar	CAHN

MINOCYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

MINOCIN

+!	REMPEX PHARMS	EQ 100MG BASE/VIAL	N050444	001			Jan	CAHN
----	---------------	--------------------	---------	-----	--	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	EQ 65MG BASE	A204453	006	Mar 16, 2018	Mar	NEWA
>A>	AB		EQ 115MG BASE	A204453	007	Mar 16, 2018	Mar	NEWA
	AB	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	Jan	CMFD
	AB		EQ 115MG BASE	A065485	005	May 18, 2012	Jan	CMFD
SOLODYN								
>D>	+	MEDICIS	EQ 65MG BASE	N050808	004	Jul 23, 2009	Mar	CTEC
>A>	AB	+	EQ 65MG BASE	N050808	004	Jul 23, 2009	Mar	CTEC
>D>	+		EQ 115MG BASE	N050808	005	Jul 23, 2009	Mar	CTEC
>A>	AB	+	EQ 115MG BASE	N050808	005	Jul 23, 2009	Mar	CTEC

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

>D>	AB	APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012	Mar	DISC
>A>		@	EQ 10MG BASE	A201294	001	Aug 03, 2012	Mar	DISC

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

>D>	AB	APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012	Mar	DISC
>A>		@	EQ 4MG BASE	A201508	001	Aug 03, 2012	Mar	DISC
>D>	AB		EQ 5MG BASE	A201508	002	Aug 03, 2012	Mar	DISC
>A>		@	EQ 5MG BASE	A201508	002	Aug 03, 2012	Mar	DISC

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	APOTEX CORP	250MG	A090419	001	Apr 22, 2009	Mar	DISC
>A>		@	250MG	A090419	001	Apr 22, 2009	Mar	DISC

TABLET; ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	APOTEX	500MG	A090499	001	Apr 22, 2009	Mar	DISC
>A>		@	500MG	A090499	001	Apr 22, 2009	Mar	DISC

NABUMETONE

TABLET; ORAL

NABUMETONE

>A>	AB	CASI PHARMS INC	500MG	A075280	001	Feb 25, 2002	Mar	CAHN
>A>	AB		750MG	A075280	002	Feb 25, 2002	Mar	CAHN
>D>	AB	SANDOZ	500MG	A075280	001	Feb 25, 2002	Mar	CAHN
>D>	AB		750MG	A075280	002	Feb 25, 2002	Mar	CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

@	FOSUN PHARMA	50MG	A075434	001	Mar 08, 2000	Jan	CAHN
---	--------------	------	---------	-----	--------------	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

@	FOSUN PHARMA	250MG	A074140	001	Dec 21, 1993	Jan	CAHN
@		375MG	A074140	002	Dec 21, 1993	Jan	CAHN
@		500MG	A074140	003	Dec 21, 1993	Jan	CAHN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

@	FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998	Jan	CAHN
@		500MG	A075061	002	Feb 18, 1998	Jan	CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB	AUROBINDO PHARMA LTD	500MG;EQ 85MG BASE	A207457	001	Feb 15, 2018	Feb	NEWA	
	TREXIMET							
AB	+!	PERNIX IRELAND LTD	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Feb	CFTG

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

>D>	AB	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Mar	DISC
>A>		@	EQ 1MG BASE	A091373	001	Apr 22, 2011	Mar	DISC
>D>	AB		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Mar	DISC
>A>		@	EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Mar	DISC
>A>	AB	CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Mar	CAHN
>A>	AB		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Mar	CAHN
>D>	AB	SANDOZ	EQ 1MG BASE	A090288	001	Jul 07, 2010	Mar	CAHN
>D>	AB		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Mar	CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

AB	+	ALLERGAN SALES LLC	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Feb	CFTG
	+		EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Jan	CAHN
AB	+		EQ 5MG BASE	N021742	003	Dec 17, 2007	Feb	CFTG
	+		EQ 5MG BASE	N021742	003	Dec 17, 2007	Jan	CAHN
AB	+		EQ 10MG BASE	N021742	004	Dec 17, 2007	Feb	CFTG
	+		EQ 10MG BASE	N021742	004	Dec 17, 2007	Jan	CAHN
AB	+		EQ 20MG BASE	N021742	005	Oct 08, 2008	Feb	CFTG
	+		EQ 20MG BASE	N021742	005	Oct 08, 2008	Jan	CAHN
<u>NEBIVOLOL HYDROCHLORIDE</u>								
>D>	AB	TORRENT PHARMS LTD	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar	DISC
>A>		@	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar	DISC
	AB		EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Feb	NEWA
>D>	AB		EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar	DISC
>A>		@	EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar	DISC
	AB		EQ 5MG BASE	A203966	002	Mar 02, 2018	Feb	NEWA
>D>	AB		EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar	DISC
>A>		@	EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar	DISC
	AB		EQ 10MG BASE	A203966	003	Mar 02, 2018	Feb	NEWA
>D>	AB		EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar	DISC
>A>		@	EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar	DISC
	AB		EQ 20MG BASE	A203966	004	Mar 02, 2018	Feb	NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

BYVALSON

+	!	ALLERGAN SALES LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Jan	CAHN
---	---	--------------------	------------------	---------	-----	--------------	-----	------

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@	FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003	Jan	CAHN
@		100MG	A076302	002	Sep 16, 2003	Jan	CAHN
@		150MG	A076302	003	Sep 16, 2003	Jan	CAHN
@		200MG	A076302	004	Sep 16, 2003	Jan	CAHN
@		250MG	A076302	005	Sep 16, 2003	Jan	CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+	!	AVADEL LEGACY	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb	CAHN
AP	+	!		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb	CAHN

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

>D>	AB	APOTEX INC	200MG	A203021	001	May 22, 2012	Mar	DISC	
>A>		@	200MG	A203021	001	May 22, 2012	Mar	DISC	
		@	TECH ORGANIZED	200MG	A203176	001	May 22, 2012	Jan	DISC
<u>TABLET, EXTENDED RELEASE; ORAL</u>									
<u>NEVIRAPINE</u>									
		@	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Jan	DISC
>D>	AB		TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017	Mar	DISC
>A>		@		100MG	A207467	001	Jul 31, 2017	Mar	DISC
>D>	AB			400MG	A207467	002	Jul 31, 2017	Mar	DISC
>A>		@		400MG	A207467	002	Jul 31, 2017	Mar	DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB	AUROBINDO PHARMA LTD	500MG	A209236	001	Feb 01, 2018	Jan	NEWA
AB		750MG	A209236	002	Feb 01, 2018	Jan	NEWA
AB		1GM	A209236	003	Feb 01, 2018	Jan	NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

>D>	+!	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Mar	DISC
>A>	+ @		40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Mar	DISC

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL
TASIGNA

>A>	+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Mar	NEWA
-----	---	----------	--------------	---------	-----	--------------	-----	------

NITROGLYCERIN

OINTMENT;INTRA-ANAL
RECTIV

	+!	ALLERGAN SALES LLC	0.4%	N021359	001	Jun 21, 2011	Jan	CAHN
AB		GLENMARK PHARMS SA	0.3MG	A206391	001	Sep 19, 2017	Jan	CAHN
AB			0.4MG	A206391	002	Sep 19, 2017	Jan	CAHN
AB			0.6MG	A206391	003	Sep 19, 2017	Jan	CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

>A>	AB	MAYNE PHARMA	EQ 10MG BASE	A073556	002	Mar 30, 1992	Mar	CMS1
>A>	AB		EQ 25MG BASE	A073556	003	Mar 30, 1992	Mar	CMS1
>A>	AB		EQ 50MG BASE	A073556	004	Mar 30, 1992	Mar	CMS1

NYSTATIN

OINTMENT;TOPICAL
NYSTATIN

	@	G AND W LABS INC	100,000 UNITS/GM	A209114	001	Oct 06, 2017	Jan	DISC
--	---	------------------	------------------	---------	-----	--------------	-----	------

SUSPENSION;ORAL
NYSTATIN

	@	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Jan	DISC
--	---	------------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		AMNEAL PHARMS LLC	100,000 UNITS/GM;0.1%	A209990	001	Feb 15, 2018	Feb	NEWA
----	--	-------------------	-----------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT		STRIDES PHARMA	100,000 UNITS/GM;0.1%	A210077	001	Jan 29, 2018	Jan	NEWA
----	--	----------------	-----------------------	---------	-----	--------------	-----	------

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

>D>	AB	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	Mar	DISC
>A>	@		5MG	A204320	001	May 30, 2017	Mar	DISC
>D>	AB		10MG	A204320	002	May 30, 2017	Mar	DISC
>A>	@		10MG	A204320	002	May 30, 2017	Mar	DISC
>D>	AB		15MG	A204320	003	May 30, 2017	Mar	DISC
>A>	@		15MG	A204320	003	May 30, 2017	Mar	DISC
>D>	AB		20MG	A204320	004	May 30, 2017	Mar	DISC
>A>	@		20MG	A204320	004	May 30, 2017	Mar	DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A>	AT	MICRO LABS LTD INDIA	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Mar	NEWA
>D>	AT	ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Mar	DISC
>A>	@		EQ 0.1% BASE	A204706	001	Dec 07, 2015	Mar	DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

>A>	@	CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006	Mar CMS1
>A>	@		8MG	A077406	004	Dec 26, 2006	Mar CMS1

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE

>A>	AB	CASI PHARMS INC	EQ 4MG BASE	A077517	001	Jun 25, 2007	Mar CAHN
>A>	AB		EQ 8MG BASE	A077517	002	Jun 25, 2007	Mar CAHN
>A>	AB		EQ 24MG BASE	A077517	003	Jun 25, 2007	Mar CAHN
>D>	AB	SANDOZ	EQ 4MG BASE	A077517	001	Jun 25, 2007	Mar CAHN
>D>	AB		EQ 8MG BASE	A077517	002	Jun 25, 2007	Mar CAHN
>D>	AB		EQ 24MG BASE	A077517	003	Jun 25, 2007	Mar CAHN

ORITAVANCIN DIPHOSPHATE

POWDER;IV (INFUSION)
ORBACTIV

>D>	+	MELINTA	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Mar CAHN
	+		EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Jan CAHN
>A>	+	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Mar CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

AB		HETERO LABS LTD III	EQ 30MG BASE	A209438	001	Feb 23, 2018	Feb NEWA
AB			EQ 45MG BASE	A209438	002	Feb 23, 2018	Feb NEWA
AB			EQ 75MG BASE	A209438	003	Feb 23, 2018	Feb NEWA

FOR SUSPENSION;ORAL
OSELTAMIVIR PHOSPHATE

AB		LUPIN ATLANTIS	EQ 6MG BASE/ML	A208347	001	Feb 20, 2018	Feb NEWA
----	--	----------------	----------------	---------	-----	--------------	----------

OXALIPLATIN

INJECTABLE;IV (INFUSION)
OXALIPLATIN

AP		ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb NEWA
AP			100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb NEWA

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL
DITROPAN XL

	+	@	JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998	Feb DISC
	+	@		10MG	N020897	002	Dec 16, 1998	Feb DISC
	+	@		15MG	N020897	003	Jun 22, 1999	Feb DISC
AB	!		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Feb CHRS

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL
OXYMORPHONE HYDROCHLORIDE

AB		ASCENT PHARMS INC	5MG	A210175	001	Feb 02, 2018	Jan NEWA
AB			10MG	A210175	002	Feb 02, 2018	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

>D>	AB	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Mar DISC
>A>	@		5MG	A203506	001	Apr 24, 2015	Mar DISC
>D>	AB		7.5MG	A203506	002	Apr 24, 2015	Mar DISC
>A>	@		7.5MG	A203506	002	Apr 24, 2015	Mar DISC
>D>	AB		10MG	A203506	003	Apr 24, 2015	Mar DISC
>A>	@		10MG	A203506	003	Apr 24, 2015	Mar DISC
>D>	AB		15MG	A203506	004	Apr 24, 2015	Mar DISC
>A>	@		15MG	A203506	004	Apr 24, 2015	Mar DISC
>D>	AB		20MG	A203506	005	Apr 24, 2015	Mar DISC
>A>	@		20MG	A203506	005	Apr 24, 2015	Mar DISC
>D>	AB		30MG	A203506	006	Apr 24, 2015	Mar DISC
>A>	@		30MG	A203506	006	Apr 24, 2015	Mar DISC
>D>	AB		40MG	A203506	007	Apr 24, 2015	Mar DISC
>A>	@		40MG	A203506	007	Apr 24, 2015	Mar DISC

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

! CASPER PHARMA LLC EQ 5MG BASE/GM;10,000 UNITS/GM N061015 001 Feb CMS2

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

>A>	AB	SUN PHARMA GLOBAL	1.5mg	A205618	001	Apr 06, 2018	Mar	NEWA
>A>	AB		3MG	A205618	002	Apr 06, 2018	Mar	NEWA
>A>	AB		6MG	A205618	003	Apr 06, 2018	Mar	NEWA
>A>	AB		9MG	A205618	004	Apr 06, 2018	Mar	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

>A>	AP	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Mar	NEWA
>A>	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Mar 23, 2018	Mar	NEWA

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

PANCREAZE

>D>	+	JANSSEN PHARMS	17,500USP UNITS;4,200USP UNITS;10,000USP UNITS	N022523	001	Apr 12, 2010	Mar	CPOT
>A>	+		24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Mar	CPOT
>D>	+		43,750USP UNITS;10,500USP UNITS;25,000USP UNITS	N022523	002	Apr 12, 2010	Mar	CPOT
>D>	+		61,000USP UNITS;21,000USP UNITS;37,000USP UNITS	N022523	003	Apr 12, 2010	Mar	CPOT
>A>	+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Mar	CPOT
>D>	+		70,000USP UNITS;16,800USP UNITS;40,000USP UNITS	N022523	004	Apr 12, 2010	Mar	CPOT
>A>	+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Mar	CPOT
>A>	+		98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Mar	CPOT

PEMOLINE

TABLET;ORAL

PEMOLINE

@	FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999	Jan	CAHN
@		37.5MG	A075286	002	Jun 30, 1999	Jan	CAHN
@		75MG	A075286	003	Jun 30, 1999	Jan	CAHN

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

PERMAPEN

BC CASPER PHARMA LLC 600,000 UNITS/ML N060014 001 Feb CMS2

PERINDOPRIL ERBUMINE

TABLET;ORAL

PERINDOPRIL ERBUMINE

@	APOTEX	2MG	A090463	001	Aug 30, 2010	Jan	DISC		
@		4MG	A090463	002	Aug 30, 2010	Jan	DISC		
@		8MG	A090463	003	Aug 30, 2010	Jan	DISC		
>D>	AB	!	AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	Mar	CHRS
>A>	AB			2MG	A079070	001	Nov 10, 2009	Mar	CHRS
>D>	AB	!		4MG	A079070	002	Nov 10, 2009	Mar	CHRS
>A>	AB			4MG	A079070	002	Nov 10, 2009	Mar	CHRS

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENDIMETRAZINE TARTRATE

>D>	+	SANDOZ	105MG	N018074	001		Mar	CAHN
>A>	+	VIRTUS PHARMS	105MG	N018074	001		Mar	CAHN

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

>D>	AA	SANDOZ	35MG	A085588	001		Mar	CAHN
>A>	AA	VIRTUS PHARMS	35MG	A085588	001		Mar	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

@ ELITE LABS INC	15MG	A040460	001	Jan 14, 2003	Jan CAHN
------------------	------	---------	-----	--------------	----------

PHENYL BUTAZONE

CAPSULE;ORAL

PHENYL BUTAZONE

@ FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982	Jan CAHN
----------------	-------	---------	-----	--------------	----------

TABLET;ORAL

PHENYL BUTAZONE

@ FOSUN PHARMA	100MG	A084339	001		Jan CAHN
----------------	-------	---------	-----	--	----------

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	VINTAGE	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jan CHRS
----	---	---------	--------------------	---------	-----	--------------	----------

PROMETH VC PLAIN

@ G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jan DISC
--------------------	--------------------	---------	-----	--------------	----------

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

AB		WOCKHARDT BIO AG	125MG/5ML	A040420	001	Apr 19, 2002	Jan CAHN
----	--	------------------	-----------	---------	-----	--------------	----------

PINDOLOL

TABLET;ORAL

PINDOLOL

>A>	AB	IDT AUSTRALIA LTD	5MG	A073609	002	Mar 29, 1993	Mar CMS1
-----	----	-------------------	-----	---------	-----	--------------	----------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		WOCKHARDT BIO AG	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan CPOT
----	--	------------------	---	---------	-----	--------------	----------

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB		LABORATORIOS CINFA	10MG	A208991	001	Feb 21, 2018	Feb NEWA
AB			20MG	A208991	002	Feb 21, 2018	Feb NEWA
AB		MICRO LABS	10MG	A206152	001	Dec 29, 2017	Feb CRLD
AB			20MG	A206152	002	Dec 29, 2017	Feb CRLD
AB		STRIDES PHARMA	10MG	A210347	001	Jan 26, 2018	Jan NEWA
AB			20MG	A210347	002	Jan 26, 2018	Jan NEWA

POLIDOCANOL

SOLUTION;INTRAVENOUS

VARITHENA

+!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Jan CDFR
----	-----------	-------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

K-TAB

AB3	+	ABBVIE	10MEQ	N018279	001		Jan CTEC
AB2	+	!	20MEQ	N018279	003	Nov 25, 2013	Jan CTEC

POTASSIUM CHLORIDE

AB3		PADDOCK LLC	10MEQ	A209688	001	Jan 12, 2018	Jan NEWA
AB2			20MEQ	A209688	002	Jan 12, 2018	Jan NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB		MOUNTAIN	5MEQ	A077440	001	Jun 09, 2006	Jan CAHN
AB			10MEQ	A077440	002	Jun 09, 2006	Jan CAHN
AB		TEVA PHARMS USA INC	5MEQ	A209758	001	Mar 05, 2018	Feb NEWA
AB			10MEQ	A209758	002	Mar 05, 2018	Feb NEWA
AB			15MEQ	A209758	003	Mar 05, 2018	Feb NEWA

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

AB	ACCORD HLTHCARE	EQ 5MG BASE	A205987	001	Feb 02, 2018	Jan	NEWA
AB		EQ 10MG BASE	A205987	002	Feb 02, 2018	Jan	NEWA
AB	USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Jan	CAHN
AB		EQ 10MG BASE	A205790	002	Oct 16, 2017	Jan	CAHN

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

@	FOSUN PHARMA	5MG	A080339	001		Jan	CAHN
---	--------------	-----	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	!	WOCKHARDT BIO AG	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan	CAHN
----	---	------------------	------------------	---------	-----	--------------	-----	------

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

AT	!	ALCON LABS INC	0.5%	A080027	001		Feb	CAHN
----	---	----------------	------	---------	-----	--	-----	------

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

@	FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003	Jan	CAHN
---	--------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

@	YAOPHARMA CO LTD	10MG	A070663	001	Jun 13, 1986	Jan	CAHN
@		20MG	A070664	001	Jun 13, 1986	Jan	CAHN
@		40MG	A070665	001	Jun 13, 1986	Jan	CAHN
@		60MG	A070666	001	Oct 10, 1986	Jan	CAHN
@		80MG	A070667	001	Jun 13, 1986	Jan	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET; ORAL

CORPHED

@	FOSUN PHARMA	60MG; 2.5MG	A088602	001	Apr 11, 1985	Jan	CAHN
---	--------------	-------------	---------	-----	--------------	-----	------

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+	!	VYERA PHARMS LLC	25MG	N008578	001		Jan	CAHN
---	---	------------------	------	---------	-----	--	-----	------

QUAZEPAM

TABLET; ORAL

DORAL

@	GALT PHARMS	7.5MG	N018708	003	Feb 26, 1987	Feb	CAHN
+	!	15MG	N018708	001	Dec 27, 1985	Feb	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@	YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001	Mar 02, 2005	Jan	CAHN
@		EQ 10MG BASE	A076803	002	Mar 02, 2005	Jan	CAHN
@		EQ 20MG BASE	A076803	003	Mar 02, 2005	Jan	CAHN
@		EQ 40MG BASE	A076803	004	Mar 02, 2005	Jan	CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

@	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Jan	DISC
---	------------------	-------	---------	-----	--------------	-----	------

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

+		CERECOR INC	5MG	N204736	001	Mar 26, 2013	Feb	CAHN
+	!		10MG	N204736	002	Mar 26, 2013	Feb	CAHN

RAMELTEONTABLET; ORAL
RAMELTEON

>D>	AB	DR REDDYS LABS INTL	8MG	A 091693	001	Jul 26, 2013	Mar	CAHN
>A>	AB	DR REDDYS LABS SA	8MG	A 091693	001	Jul 26, 2013	Mar	CAHN

RAMIPRILCAPSULE; ORAL
RAMIPRIL

>D>	AB	WATSON LABS	5MG	A 076549	003	Oct 24, 2005	Mar	DISC
>A>		@	5MG	A 076549	003	Oct 24, 2005	Mar	DISC
		@ YAOPHARMA CO LTD	1.25MG	A 077514	001	Jun 18, 2008	Jan	CAHN
		@	2.5MG	A 077514	002	Jun 18, 2008	Jan	CAHN
		@	5MG	A 077514	003	Jun 18, 2008	Jan	CAHN
		@	10MG	A 077514	004	Jun 18, 2008	Jan	CAHN

RASAGILINE MESYLATETABLET; ORAL
RASAGILINE MESYLATE

>D>	AB	APOTEX INC	EQ 0.5MG BASE	A 201950	001	Sep 12, 2013	Mar	DISC
>A>		@	EQ 0.5MG BASE	A 201950	001	Sep 12, 2013	Mar	DISC
>D>	AB		EQ 1MG BASE	A 201950	002	Sep 12, 2013	Mar	DISC
>A>		@	EQ 1MG BASE	A 201950	002	Sep 12, 2013	Mar	DISC

REMIFENTANIL HYDROCHLORIDEINJECTABLE; INJECTION
REMIFENTANIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 1MG BASE/VIAL	A 206223	001	Jan 16, 2018	Jan	NEWA
AP			EQ 2MG BASE/VIAL	A 206223	002	Jan 16, 2018	Jan	NEWA
AP			EQ 5MG BASE/VIAL	A 206223	003	Jan 16, 2018	Jan	NEWA
		ULTIVA						
AP	+	MYLAN INSTITUTIONAL	EQ 1MG BASE/VIAL	N 020630	001	Jul 12, 1996	Jan	CFTG
AP	+		EQ 2MG BASE/VIAL	N 020630	002	Jul 12, 1996	Jan	CFTG
AP	+	!	EQ 5MG BASE/VIAL	N 020630	003	Jul 12, 1996	Jan	CFTG

REPAGLINIDETABLET; ORAL
REPAGLINIDE

>A>	AB	CASI PHARMS INC	0.5MG	A 078555	001	Nov 22, 2013	Mar	CAHN
>A>	AB		1MG	A 078555	002	Jan 22, 2014	Mar	CAHN
>A>	AB		2MG	A 078555	003	Jan 22, 2014	Mar	CAHN
>D>	AB	SANDOZ INC	0.5MG	A 078555	001	Nov 22, 2013	Mar	CAHN
>D>	AB		1MG	A 078555	002	Jan 22, 2014	Mar	CAHN
>D>	AB		2MG	A 078555	003	Jan 22, 2014	Mar	CAHN

RIBAVIRINCAPSULE; ORAL
RIBAVIRIN

>A>	AB	CASI PHARMS INC	200MG	A 076192	001	Apr 06, 2004	Mar	CAHN
>D>	AB	SANDOZ	200MG	A 076192	001	Apr 06, 2004	Mar	CAHN

RISPERIDONESOLUTION; ORAL
RISPERIDONE

>D>	AA	PRECISION DOSE	1MG/ML	A 076797	001	Jun 28, 2010	Mar	DISC
>A>		@	1MG/ML	A 076797	001	Jun 28, 2010	Mar	DISC

TABLET; ORAL
RISPERIDONE

>A>	AB	CHARTWELL MOLECULAR	0.25MG	A 077543	001	May 18, 2011	Mar	CAHN
>A>	AB		0.5MG	A 077543	002	May 18, 2011	Mar	CAHN
>A>	AB		1MG	A 077543	003	May 18, 2011	Mar	CAHN
>A>	AB		2MG	A 077543	004	May 18, 2011	Mar	CAHN
>A>	AB		3MG	A 077543	005	May 18, 2011	Mar	CAHN
>A>	AB		4MG	A 077543	006	May 18, 2011	Mar	CAHN
>D>	AB	CIPLA	0.25MG	A 077543	001	May 18, 2011	Mar	CAHN
>D>	AB		0.5MG	A 077543	002	May 18, 2011	Mar	CAHN
>D>	AB		1MG	A 077543	003	May 18, 2011	Mar	CAHN
>D>	AB		2MG	A 077543	004	May 18, 2011	Mar	CAHN
>D>	AB		3MG	A 077543	005	May 18, 2011	Mar	CAHN
>D>	AB		4MG	A 077543	006	May 18, 2011	Mar	CAHN
	AB	RENATA	0.25MG	A 078707	001	Dec 29, 2008	Jan	CAHN

TABLET;ORAL
RISPERIDONE

AB		0.5MG	A078707	002	Dec 29, 2008	Jan CAHN
AB		1MG	A078707	003	Dec 29, 2008	Jan CAHN
AB		2MG	A078707	004	Dec 29, 2008	Jan CAHN
AB		3MG	A078707	005	Dec 29, 2008	Jan CAHN
AB		4MG	A078707	006	Dec 29, 2008	Jan CAHN

RIZATRIPTAN BENZOATE

TABLET;ORAL
RIZATRIPTAN BENZOATE

>D>	AB	APOTEX INC	EQ 5MG BASE	A202244	001	Dec 31, 2012	Mar DISC
>A>		@	EQ 5MG BASE	A202244	001	Dec 31, 2012	Mar DISC
>D>	AB		EQ 10MG BASE	A202244	002	Dec 31, 2012	Mar DISC
>A>		@	EQ 10MG BASE	A202244	002	Dec 31, 2012	Mar DISC

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

>D>	AB	APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013	Mar DISC
>A>		@	EQ 5MG BASE	A202477	001	Jul 01, 2013	Mar DISC
>D>	AB		EQ 10MG BASE	A202477	002	Jul 01, 2013	Mar DISC
>A>		@	EQ 10MG BASE	A202477	002	Jul 01, 2013	Mar DISC

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

>A>	AP	GLAND CHEMS PVT	50MG/5ML (10MG/ML)	A205656	001	Apr 04, 2018	Mar NEWA
>A>	AP		100MG/10ML (10MG/ML)	A205656	002	Apr 04, 2018	Mar NEWA

ROFLUMILAST

TABLET;ORAL
DALIRESP

+	ASTRAZENECA PHARMS	250MCG	N022522	002	Jan 23, 2018	Jan NEWA
---	--------------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

@	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Jan DISC
@		EQ 0.5MG BASE	A077460	002	May 05, 2008	Jan DISC
@		EQ 1MG BASE	A077460	003	May 05, 2008	Jan DISC
@		EQ 2MG BASE	A077460	004	May 05, 2008	Jan DISC
@		EQ 3MG BASE	A077460	005	May 05, 2008	Jan DISC
@		EQ 4MG BASE	A077460	006	May 05, 2008	Jan DISC
@		EQ 5MG BASE	A077460	007	May 19, 2008	Jan DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
NAROPIN

>D>	+	FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar CTEC
>A>	AP	+	400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar CTEC

ROPIVACAINE HYDROCHLORIDE

>A>	AP	AKORN	200MG/100ML (2MG/ML)	A204636	001	Mar 16, 2018	Mar NEWA
>A>	AP		400MG/200ML (2MG/ML)	A204636	002	Mar 16, 2018	Mar NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL
SERTRALINE HYDROCHLORIDE

>A>	@	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162	001	Feb 06, 2007	Mar CAHN
>A>	@		EQ 50MG BASE	A077162	002	Feb 06, 2007	Mar CAHN
>A>	@		EQ 100MG BASE	A077162	003	Feb 06, 2007	Mar CAHN
>D>	@	CIPLA LTD	EQ 25MG BASE	A077162	001	Feb 06, 2007	Mar CAHN
>D>	@		EQ 50MG BASE	A077162	002	Feb 06, 2007	Mar CAHN
>D>	@		EQ 100MG BASE	A077162	003	Feb 06, 2007	Mar CAHN
@	FOSUN PHARMA		EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan CAHN
@			EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan CAHN
@			EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan CAHN

SEVELAMER CARBONATE

TABLET;ORAL
SEVELAMER CARBONATE

>A>	AB	SANDOZ INC	800MG	A200959	001	Mar 20, 2018	Mar NEWA
-----	----	------------	-------	---------	-----	--------------	----------

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

>D>	AB	APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012	Mar	DISC
>A>		@	EQ 20MG BASE	A091379	001	Nov 06, 2012	Mar	DISC

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

	@	YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006	Jan	CAHN
	@		10MG	A077766	002	Dec 20, 2006	Jan	CAHN
	@		20MG	A077766	003	Dec 20, 2006	Jan	CAHN
	@		40MG	A077766	004	Dec 20, 2006	Jan	CAHN
	@		80MG	A077766	005	Dec 20, 2006	Jan	CAHN

SINECATECHINS

OINTMENT;TOPICAL

VEREGEN

+!		FOUGERA PHARMS INC	15%	N021902	001	Oct 31, 2006	Jan	CAHN
----	--	--------------------	-----	---------	-----	--------------	-----	------

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

>D>		HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Mar	DISC
>A>		@	0.5MEQ/ML	A202679	001	Mar 07, 2017	Mar	DISC
>D>			0.5MEQ/ML	A202981	001	Mar 04, 2016	Mar	DISC
>A>		@	0.5MEQ/ML	A202981	001	Mar 04, 2016	Mar	DISC

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+!	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Feb	CAHN
----	----	-----------------	--------	---------	-----	--------------	-----	------

SOLUTION;IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AT	B BRAUN	900MG/100ML	N016733	001		Mar	CRLD
>A>	AT	+!	900MG/100ML	N016733	001		Mar	CRLD

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN
----	--	-------	--------------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

>D>	AA	AILEX PHARMS LLC	454GM/BOT	A206815	001	Feb 18, 2016	Mar	CAHN
>A>	AA	APNAR PHARMA LP	454GM/BOT	A206815	001	Feb 18, 2016	Mar	CAHN

SOMATROPIN

INJECTABLE;INJECTION

BIO-TROPIN

	@	FERRING	4.8MG/VIAL	N019774	001	May 25, 1995	Feb	CAIN
--	---	---------	------------	---------	-----	--------------	-----	------

ZOMACTON

BX	+!	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Feb	CAIN
	+		10MG/VIAL	N019774	003	Mar 07, 2012	Feb	CAIN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

>A>	AB	CASI PHARMS INC	25MG	A086809	001		Mar	CAHN
>D>	AB	SANDOZ	25MG	A086809	001		Mar	CAHN

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

>D>	AT	B BRAUN	100%	N016734	001		Mar	CRLD
>A>	AT	+	100%	N016734	001		Mar	CRLD

SUCRALFATE

	SUSPENSION;ORAL								
	CARAFATE								
	+!	ALLERGAN SALES LLC	1GM/10ML		N019183	001	Dec 16, 1993	Jan	CAHN
	TABLET;ORAL								
	CARAFATE								
AB	+!	ALLERGAN SALES LLC	1GM		N018333	001		Jan	CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

	TABLET;ORAL								
	SULFAMETHOXAZOLE AND TRIMETHOPRIM								
	@	FOSUN PHARMA	400MG;80MG		A070889	001	Nov 13, 1986	Jan	CAHN
	@		400MG;80MG		N018598	003	May 19, 1982	Jan	CAHN
	@		800MG;160MG		A070890	001	Nov 13, 1986	Jan	CAHN
	SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH								
	@	FOSUN PHARMA	800MG;160MG		N018598	004	May 19, 1982	Jan	CAHN

SULINDAC

	TABLET;ORAL								
	SULINDAC								
	@	FOSUN PHARMA	150MG		A072712	001	Aug 30, 1991	Jan	CAHN
	@		200MG		A072713	001	Aug 30, 1991	Jan	CAHN

SUMATRIPTAN SUCCINATE

	INJECTABLE;SUBCUTANEOUS								
>D>	SUMAVEL DOSEPRO								
>D> BX	+!	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N022239	002	Nov 26, 2013	Mar	DISC
>A>	+ @		EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)		N022239	002	Nov 26, 2013	Mar	DISC
>D> BX	+!		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N022239	001	Jul 15, 2009	Mar	DISC
>A>	+ @		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)		N022239	001	Jul 15, 2009	Mar	DISC
	TABLET;ORAL								
	SUMATRIPTAN SUCCINATE								
	@	FOSUN PHARMA	EQ 25MG BASE		A076976	001	Aug 10, 2009	Jan	CAHN
	@		EQ 50MG BASE		A076976	002	Aug 10, 2009	Jan	CAHN
	@		EQ 100MG BASE		A076976	003	Aug 10, 2009	Jan	CAHN

TALC

	AEROSOL;INTRAPLEURAL								
	SCLEROSOL								
>A>	+!	LYMOL MEDCL	4GM/SPRAY		N020587	001	Dec 24, 1997	Mar	CPOT
	AEROSOL, METERED;INTRAPLEURAL								
	SCLEROSOL								
>D>	+!	LYMOL MEDCL	400MG/SPRAY		N020587	001	Dec 24, 1997	Mar	CPOT

TAMOXIFEN CITRATE

	SOLUTION;ORAL								
	SOLTAMOX								
>D>		MIDATECH PHARMA US	EQ 10MG BASE/5ML		N021807	001	Oct 29, 2005	Mar	CPOT
>A>			EQ 20MG BASE/10ML		N021807	001	Oct 29, 2005	Mar	CPOT

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

	INJECTABLE;INJECTION								
	PULMOLITE								
	+ @	JUBILANT DRAXIMAGE	N/A		N017776	001		Feb	DISC

TECHNETIUM TC-99M MEDRONATE KIT

	INJECTABLE;INJECTION								
	CIS-MDP								
		PHARMALUCENCE	N/A		N018124	001		Jan	CTEC
		MDP-BRACCO							
	@	CARDINAL HEALTH 414	N/A		N018107	001		Jan	DISC

TECHNETIUM TC-99M PENTETATE KIT

	INJECTABLE;INJECTION								
	DTPA								
	+!	JUBILANT DRAXIMAGE	N/A		N018511	001	Dec 29, 1989	Jan	CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION;INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM

+ NORTHSTAR MEDICAL 30-1153mCi/GENERATOR N202158 001 Feb 08, 2018 Feb NEWA

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

>D>	AB	MYLAN PHARMS INC	100MG	A205227	003	Jun 29, 2016	Mar	DISC
>A>		@	100MG	A205227	003	Jun 29, 2016	Mar	DISC
>D>	AB		140MG	A205227	004	Jun 29, 2016	Mar	DISC
>A>		@	140MG	A205227	004	Jun 29, 2016	Mar	DISC
>D>	AB		180MG	A205227	005	Jun 29, 2016	Mar	DISC
>A>		@	180MG	A205227	005	Jun 29, 2016	Mar	DISC
>D>	AB		250MG	A205227	006	Jun 29, 2016	Mar	DISC
>A>		@	250MG	A205227	006	Jun 29, 2016	Mar	DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB		AUROBINDO PHARMA LTD	150MG	A090647	001	Jan 26, 2018	Jan	NEWA
AB			200MG	A090647	002	Jan 26, 2018	Jan	NEWA
AB			250MG	A090647	003	Jan 26, 2018	Jan	NEWA
AB			300MG	A090647	004	Jan 26, 2018	Jan	NEWA
AB		CIPLA LTD	300MG	A078800	001	Jan 26, 2018	Jan	NEWA
AB		HETERO LABS LTD III	300MG	A090636	001	Jan 26, 2018	Jan	NEWA
AB		LAURUS LABS PVT	300MG	A209550	001	Feb 26, 2018	Feb	NEWA
AB		MACLEODS PHARMS LTD	300MG	A203232	001	Jan 26, 2018	Jan	NEWA
AB		QILU TIANHE	200MG	A209498	001	Mar 02, 2018	Feb	NEWA
AB			250MG	A209498	002	Mar 02, 2018	Feb	NEWA
AB			300MG	A209498	003	Mar 02, 2018	Feb	NEWA
AB		STRIDES PHARMA	300MG	A090742	001	Jan 26, 2018	Jan	NEWA
AB		TEVA PHARMS USA	150MG	A091612	002	Jan 26, 2018	Jan	NEWA
AB			200MG	A091612	003	Jan 26, 2018	Jan	NEWA
AB			250MG	A091612	004	Jan 26, 2018	Jan	NEWA
AB	+	GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Jan	CFTG
AB	+		200MG	N021356	003	Jan 18, 2012	Jan	CFTG
AB	+		250MG	N021356	004	Jan 18, 2012	Jan	CFTG

TERCONAZOLE

CREAM;VAGINAL

TERAZOL 7

+	@	JANSSEN PHARMS	0.4%	N019579	001	Dec 31, 1987	Feb	DISC
AB	!	TARO	0.4%	A076043	001	Jan 19, 2005	Feb	CHRS
		SUPPOSITORY;VAGINAL						
		TERAZOL 3						
+	@	JANSSEN PHARMS	80MG	N019641	001	May 24, 1988	Feb	DISC
		TERCONAZOLE						
AB	!	PERRIGO NEW YORK	80MG	A077149	001	Mar 17, 2006	Feb	CHRS

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

	@	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jan	DISC
	@		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jan	DISC
		SOLUTION, METERED;TRANSDERMAL						
		TESTOSTERONE						
AT		CIPLA LTD	30MG/1.5ML ACTUATION	A209533	001	Jan 29, 2018	Jan	NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

>A>	+	ALCON LABS	0.5%	N208135	001	Feb 29, 2016	Mar	CAHN
>D>	+	NOVARTIS PHARMS CORP	0.5%	N208135	001	Feb 29, 2016	Mar	CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOCHRON

AB	NOSTRUM PHARMS LLC	100MG	A087400	003	Feb 21, 1985	Jan	CTEC
AB		200MG	A087400	004	Feb 21, 1985	Jan	CTEC

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

@	FOSUN PHARMA	10MG	A088131	001	Aug 30, 1983	Jan	CAHN
@		15MG	A088132	001	Aug 30, 1983	Jan	CAHN
@		25MG	A088133	001	Aug 30, 1983	Jan	CAHN
@		50MG	A088134	001	Aug 30, 1983	Jan	CAHN
@		100MG	A088135	001	Nov 20, 1984	Jan	CAHN
@		150MG	A088136	001	Sep 17, 1986	Jan	CAHN
@		200MG	A088137	001	Sep 17, 1986	Jan	CAHN

THIOTHIXENE

CAPSULE;ORAL

NAVANE

+	@	PFIZER	1MG	N016584	001		Jan	CRLD
+	@		2MG	N016584	002		Jan	CRLD
+	@		5MG	N016584	003		Jan	CRLD
+	@		10MG	N016584	004		Jan	CRLD
+	@		20MG	N016584	005		Jan	CRLD

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

@	YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Jan	CAHN
@		250MG	A075326	001	Aug 20, 1999	Jan	CAHN

TIGECYCLINE

POWDER;IV (INFUSION)

TIGECYCLINE

	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jan	NEWA
--	---------------------	-----------	---------	-----	--------------	-----	------

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOPTIC

AT	+	ATON	EQ 0.25% BASE	N018086	001		Jan	CMFD
AT1	+		EQ 0.5% BASE	N018086	002		Jan	CMFD

TABLET;ORAL

TIMOLOL MALEATE

@	YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989	Jan	CAHN
@		10MG	A072551	001	Apr 13, 1989	Jan	CAHN
@		20MG	A072552	001	Apr 13, 1989	Jan	CAHN

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

>A>	AB	CASI PHARMS INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Mar	CAHN
>A>	AB		EQ 4MG BASE	A076280	002	Jun 27, 2002	Mar	CAHN
>D>	AB	SANDOZ INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Mar	CAHN
>D>	AB		EQ 4MG BASE	A076280	002	Jun 27, 2002	Mar	CAHN
	AB	ZYDUS PHARMS USA INC	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	NEWA
	AB		EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	NEWA

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@	YAOPHARMA CO LTD	100MG	A071633	001	Dec 09, 1987	Jan	CAHN
@		250MG	A070289	001	Mar 13, 1986	Jan	CAHN
@		500MG	A070290	001	Mar 13, 1986	Jan	CAHN

TOLBUTAMIDE

TABLET;ORAL

TOLBUTAMIDE

@	YAOPHARMA CO LTD	500MG	A086574	001		Jan	CAHN
---	------------------	-------	---------	-----	--	-----	------

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA	EQ 400MG BASE	A 073462	001	Apr 30, 1992	Jan CAHN
----------------	---------------	----------	-----	--------------	----------

TABLET;ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA	EQ 200MG BASE	A 073588	001	Jul 31, 1992	Jan CAHN
----------------	---------------	----------	-----	--------------	----------

@	EQ 600MG BASE	A 074002	001	Sep 27, 1993	Jan CAHN
---	---------------	----------	-----	--------------	----------

TOLTERODINE TARTRATE

TABLET;ORAL

TOLTERODINE TARTRATE

>D> AB	APOTEX CORP	1MG	A 200164	001	Sep 25, 2012	Mar DISC
--------	-------------	-----	----------	-----	--------------	----------

>A>	@	1MG	A 200164	001	Sep 25, 2012	Mar DISC
-----	---	-----	----------	-----	--------------	----------

>D> AB		2MG	A 200164	002	Sep 25, 2012	Mar DISC
--------	--	-----	----------	-----	--------------	----------

>A>	@	2MG	A 200164	002	Sep 25, 2012	Mar DISC
-----	---	-----	----------	-----	--------------	----------

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

@ FOSUN PHARMA	15MG	A 079206	001	Oct 14, 2009	Jan CAHN
----------------	------	----------	-----	--------------	----------

@	25MG	A 079206	002	Oct 14, 2009	Jan CAHN
---	------	----------	-----	--------------	----------

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

@ FOSUN PHARMA	50MG	A 075968	001	Jun 25, 2002	Jan CAHN
----------------	------	----------	-----	--------------	----------

TRANDOLAPRIL

TABLET;ORAL

MAVIK

>D> AB	+ ABBVIE	1MG	N 020528	001	Apr 26, 1996	Mar DISC
--------	----------	-----	----------	-----	--------------	----------

>A>	+ @	1MG	N 020528	001	Apr 26, 1996	Mar DISC
-----	-----	-----	----------	-----	--------------	----------

>D> AB	+	2MG	N 020528	002	Apr 26, 1996	Mar DISC
--------	---	-----	----------	-----	--------------	----------

>A>	+ @	2MG	N 020528	002	Apr 26, 1996	Mar DISC
-----	-----	-----	----------	-----	--------------	----------

>D> AB	+!	4MG	N 020528	003	Apr 26, 1996	Mar DISC
--------	----	-----	----------	-----	--------------	----------

>A>	+ @	4MG	N 020528	003	Apr 26, 1996	Mar DISC
-----	-----	-----	----------	-----	--------------	----------

TRANDOLAPRIL

>D> AB	LUPIN	4MG	A 077522	003	Jun 12, 2007	Mar CHRS
--------	-------	-----	----------	-----	--------------	----------

>A> AB	!	4MG	A 077522	003	Jun 12, 2007	Mar CHRS
--------	---	-----	----------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

@ FOSUN PHARMA	100MG	A 072483	001	Apr 30, 1990	Jan CAHN
----------------	-------	----------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT	PERRIGO NEW YORK	0.025%	A 086413	002		Mar CMS1
--------	------------------	--------	----------	-----	--	----------

>A> AT		0.1%	A 086413	003		Mar CMS1
--------	--	------	----------	-----	--	----------

SPRAY;TOPICAL

KENALOG

AT	+!	SUN PHARM INDS INC	0.147MG/GM	N 012104	001	Feb CAHN
----	----	--------------------	------------	----------	-----	----------

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

SYPRINE

AB	+!	ATON	250MG	N 019194	001	Nov 08, 1985	Jan CFTG
----	----	------	-------	----------	-----	--------------	----------

TRIENTINE HYDROCHLORIDE

AB		WATSON LABS TEVA	250MG	A 207567	001	Feb 07, 2018	Jan NEWA
----	--	------------------	-------	----------	-----	--------------	----------

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

@ FOSUN PHARMA	EQ 10MG BASE/ML	A 085787	001	Apr 15, 1982	Jan CAHN
----------------	-----------------	----------	-----	--------------	----------

VALSARTANTABLET; ORAL
VALSARTAN

>A>	AB	SQUARE PHARMS LTD	40MG	A205347	001	Apr 09, 2018	Mar	NEWA
>A>	AB		80MG	A205347	002	Apr 09, 2018	Mar	NEWA
>A>	AB		160MG	A205347	003	Apr 09, 2018	Mar	NEWA
>A>	AB		320MG	A205347	004	Apr 09, 2018	Mar	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

@	FRESENIUS KABI USA	EQ 125MG BASE	A065453	001	Jun 18, 2012	Feb	DISC
@		EQ 250MG BASE	A065453	002	Jun 18, 2012	Feb	DISC

FOR SOLUTION; ORAL

FIRVANQ KIT

+	!	RXMTM THERAPS LLC	EQ 25MG BASE/ML	N208910	001	Jan 26, 2018	Jan	NEWA
+	!		EQ 50MG BASE/ML	N208910	002	Jan 26, 2018	Jan	NEWA

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

>D>	AP	MYLAN LABS LTD	EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Mar	DISC
>A>		@	EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Mar	DISC

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

+		PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Feb	CAHN
+	!		EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

@	FOSUN PHARMA	EQ 25MG BASE	A077515	001	Jun 13, 2008	Jan	CAHN
@		EQ 37.5MG BASE	A077515	002	Jun 13, 2008	Jan	CAHN
@		EQ 50MG BASE	A077515	003	Jun 13, 2008	Jan	CAHN
@		EQ 75MG BASE	A077515	004	Jun 13, 2008	Jan	CAHN
@		EQ 100MG BASE	A077515	005	Jun 13, 2008	Jan	CAHN

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	!	HOSPIRA	5MG/2ML (2.5MG/ML)	A070738	001	May 06, 1987	Jan	CPOT
----	---	---------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

@	YAOPHARMA CO LTD	40MG	A073168	001	Jul 31, 1992	Jan	CAHN
@		80MG	A071423	001	May 24, 1988	Jan	CAHN
@		120MG	A071424	001	May 25, 1988	Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

>D>	AB	APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Mar	DISC
>A>		@	120MG	A200878	001	Apr 20, 2012	Mar	DISC
>D>	AB		180MG	A200878	002	Apr 20, 2012	Mar	DISC
>A>		@	180MG	A200878	002	Apr 20, 2012	Mar	DISC
>D>	AB		240MG	A200878	003	Apr 20, 2012	Mar	DISC
>A>		@	240MG	A200878	003	Apr 20, 2012	Mar	DISC

VIGABATRIN

FOR SOLUTION; ORAL

VIGABATRIN

AA		AMNEAL PHARMS	500MG/PACKET	A210155	001	Mar 13, 2018	Feb	NEWA
----	--	---------------	--------------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	!	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011	Jan	CAHN
+			20MG	N022567	002	Jan 21, 2011	Jan	CAHN
+			40MG	N022567	003	Jan 21, 2011	Jan	CAHN

WARFARIN SODIUM

TABLET;ORAL

WARFARIN SODIUM

@	YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997	Jan	CAHN
@		2MG	A040196	002	Sep 30, 1997	Jan	CAHN
@		2.5MG	A040196	003	Sep 30, 1997	Jan	CAHN
@		3MG	A040196	008	Jul 26, 2000	Jan	CAHN
@		4MG	A040196	004	Sep 30, 1997	Jan	CAHN
@		5MG	A040196	005	Sep 30, 1997	Jan	CAHN
@		6MG	A040196	009	Jul 26, 2000	Jan	CAHN
@		7.5MG	A040196	006	Sep 30, 1997	Jan	CAHN
@		10MG	A040196	007	Sep 30, 1997	Jan	CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

>D>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Mar	DISC
>A>		@	EQ 20MG BASE	A202395	001	Oct 10, 2013	Mar	DISC
>D>	AB		EQ 40MG BASE	A202395	002	Oct 10, 2013	Mar	DISC
>A>		@	EQ 40MG BASE	A202395	002	Oct 10, 2013	Mar	DISC
>D>	AB		EQ 60MG BASE	A202395	003	Oct 10, 2013	Mar	DISC
>A>		@	EQ 60MG BASE	A202395	003	Oct 10, 2013	Mar	DISC

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP		INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan	CAHN
AP			EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan	CAHN

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

>D>	AB	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Mar	DISC
>A>		@	2.5MG	A202078	001	May 14, 2013	Mar	DISC
>D>	AB		5MG	A202078	002	May 14, 2013	Mar	DISC
>A>		@	5MG	A202078	002	May 14, 2013	Mar	DISC

TABLET, ORALLY DISINTEGRATING;ORAL

ZOLMITRIPTAN

>D>	AB	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Mar	DISC
>A>		@	2.5MG	A202476	001	May 14, 2013	Mar	DISC
>D>	AB		5MG	A202476	002	May 14, 2013	Mar	DISC
>A>		@	5MG	A202476	002	May 14, 2013	Mar	DISC

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

@	AUROBINDO PHARMA LTD	25MG	A077645	002	Sep 29, 2006	Feb	CAHN
@		50MG	A077645	003	Sep 29, 2006	Feb	CAHN
@		100MG	A077645	001	Dec 22, 2005	Feb	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ G AND W LABS

325MG

N018060 003 Dec 18, 1986

Jan DISC

@

650MG

N018060 002

Jan DISC

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

PLD ACQUISITIONS

5MG

A077946 001 Dec 27, 2007

Feb CAHN

10MG

A077946 002 Dec 27, 2007

Feb CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

PLD ACQUISITIONS

5MG;120MG

A077991 001 Mar 05, 2008

Feb CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+! BECTON DICKINSON CO

2%;70% (1ML)

N020832 008 Oct 23, 2008

Feb NEWA

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

PLD ACQUISITIONS LLC

1.34MG

A073458 001 Oct 31, 1993

Jan CAHN

CLOTTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

>D>

BAYER HEALTHCARE LLC

1%

N018230 002 Dec 26, 1991

Mar DISC

>A>

@

1%

N018230 002 Dec 26, 1991

Mar DISC

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

@ BAYER HEALTHCARE LLC

1%,100MG

N020389 002 Jun 23, 1994

Feb DISC

>D>

TABLET;VAGINAL

>D>

MYCELEX-7

>D>

BAYER HEALTHCARE LLC

100MG

N018182 002 Dec 26, 1991

Mar DISC

>A>

@

100MG

N018182 002 Dec 26, 1991

Mar DISC

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

>A>

STRIDES PHARMA

EQ 200MG FREE ACID AND POTASSIUM SALT

A204469 001 Mar 28, 2018

Mar NEWA

TABLET;ORAL

IBUPROFEN

@ P AND L DEV LLC

200MG

A070733 001 Sep 19, 1986

Jan CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD

5MG

A210375 001 Jan 19, 2018

Jan NEWA

LORATADINE

TABLET;ORAL

LORATADINE

PLD ACQUISITIONS LLC

10MG

A075209 001 Jan 21, 2003

Jan CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

>A>

AUROBINDO PHARMA LTD

10MG

A208477 001 Apr 11, 2018

Mar NEWA

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MICONAZOLE 7 COMBINATION PACK

@ G AND W LABS

2%,100MG

A076585 001 Mar 26, 2004

Jan DISC

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

@ PLD ACQUISITIONS LLC EQ 200MG BASE

A074646 001 Jan 13, 1997 Jan CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

THRIVE

>D>

GLAXOSMITHKLINE CONS EQ 2MG BASE

A077658 001 Jun 19, 2007 Mar DISC

>D>

@ EQ 2MG BASE

A077658 001 Jun 19, 2007 Mar DISC

>A>

EQ 2MG BASE

A077658 001 Jun 19, 2007 Feb CAHN

EQ 4MG BASE

A077656 001 Jun 19, 2007 Feb CAHN

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE CONS EQ 2MG BASE

N021330 001 Oct 31, 2002 Feb CTNA

+! EQ 4MG BASE

N021330 002 Oct 31, 2002 Feb CTNA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

>A>

ZYDUS PHARMS USA INC 20MG;1.1GM

A203345 001 Mar 16, 2018 Mar NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

>D>

AILEX PHARMS LLC 17GM/SCOOPFUL

A202071 001 Dec 28, 2012 Mar CAHN

>A>

APNAR PHARMA LP 17GM/SCOOPFUL

A202071 001 Dec 28, 2012 Mar CAHN

>A>

AUROBINDO PHARMA LTD 17GM/SCOOPFUL

A209017 001 Apr 09, 2018 Mar NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

VIVIMED GLOBAL EQ 75MG BASE

A209160 001 Mar 05, 2018 Feb NEWA

EQ 150MG BASE

A209161 001 Feb 22, 2018 Feb NEWA

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021958 001 Jul 24, 2006 Feb CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021124 001 Mar 17, 2000 Feb CAHN

SPRAY;TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE CONS 1%

N021124 002 Mar 17, 2000 Feb CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2018

NO MARCH 2018 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	>A> 7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	>A> 7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	>A> 7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	>A> 7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
	>A> 7855211	Dec 15, 2029	DS DP U-2132			
	>A> 7855211	Dec 15, 2029	DS DP U-2135			
	>A> 7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580			
	8822438	Aug 24, 2027	U-2235			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579		I-765	Feb 07, 2021
	8822438	Aug 24, 2027	U-1580			
	8822438	Aug 24, 2027	U-2235			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	>A> 8461137	Feb 22, 2031	DS DP			
	>A> 8748413	Jul 01, 2030	DS DP			
	>A> 8828978	Jul 01, 2030	DP			
	>A> 9132125	Jul 01, 2030	DS DP U-2249			
	>A> 9549923	Jul 01, 2030	DS DP			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001					I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002					I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003					I-763	Jan 12, 2021
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	>A> 9861771	Oct 11, 2020	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	9867791	Dec 02, 2030	U-2106		>A> I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	9867791	Dec 02, 2030	U-2106		>A> I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	9867791	Dec 02, 2030	U-2106		>A> I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001					>A> I-766	Mar 09, 2021
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	8445507	Sep 15, 2030	DS DP U-2237		NCE	Feb 14, 2023
	8802689	Mar 27, 2027	U-2237			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9884054	Sep 23, 2033	U-2237			
<u>APREMILAST - OTEZLA</u>						
N 205437 001 >A>	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 002 >A>	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 003 >A>	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-2204			
	6723351	Nov 10, 2018	U-2229			
	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-2204			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6855339	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002 >A>	6723351	Nov 10, 2018	U-2204			
>A>	6723351	Nov 10, 2018	U-2229			
>A>	6855339	Nov 10, 2018	U-2204			
>A>	6855339	Nov 10, 2018	U-2229			
>A>	6861076	Nov 10, 2018	U-2204			
>A>	6861076	Nov 10, 2018	U-2229			
>A>	6884439	Nov 10, 2018	U-2204			
>A>	6884439	Nov 10, 2018	U-2229			
>A>	6982096	Nov 10, 2018	U-2204			
>A>	6982096	Nov 10, 2018	U-2229			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002 >A>	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001 >A>	9901585	Jun 13, 2023	DP			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	5998402	Apr 04, 2019	DS DP U-594			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	8791270	Jan 12, 2026	DP U-1790			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	9877974	Aug 31, 2030	DP U-1858			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	6642245	Nov 04, 2020		U-257	NCE	Feb 07, 2023
	6703396	Mar 09, 2021	DS DP			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022		U-257		
	8754065	Aug 15, 2032	DS DP	U-257		
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP	U-257		
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002					ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003					ODE-163	Dec 19, 2024
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	9861631	Mar 25, 2031		U-1428		
	9861632	Mar 25, 2031		U-1428		
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	8293742	Jul 14, 2030		U-2222		
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	9907801	Apr 19, 2022	DP	U-2239		
	9907802	Apr 19, 2022	DP	U-2240		
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					NP	Nov 30, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					NP	Nov 30, 2020
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	>A> 9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	>A> 9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	>A> 9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	>A> 9901539	Dec 21, 2032		U-1556		
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	>A> 9901539	Dec 21, 2032		U-1556		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	>A> 9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	>A> 9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	>A> 9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	>A> 9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	>A> 9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	>A> 9931305	Feb 14, 2022	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	9861644	Mar 14, 2034	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427 9901640	May 29, 2022 Dec 26, 2028	DP U-1645 DP U-219	Y		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427 9901640	May 29, 2022 Dec 26, 2028	DP U-1645 DP U-219	Y		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427 9901640	May 29, 2022 Dec 26, 2028	DP U-1645 DP U-219	Y		
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427 9901640	May 29, 2022 Dec 26, 2028	DP U-1645 DP U-219	Y		
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9872906	Mar 14, 2034	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524 001					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524 002					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003					M-221	Feb 14, 2021
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	>A> 9603796	Apr 21, 2029	DS DP U-2252		>A> I-770	Mar 02, 2021
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	9889115	Jun 23, 2019	U-1660			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	9891239	Sep 03, 2029	DP U-257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	9891239	Sep 03, 2029	DP U-257			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	9867815	Feb 07, 2037	U-2225		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					ODE-162	Dec 22, 2024
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002					ODE-162	Dec 22, 2024
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002 >A>	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004 >A>	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005 >A>	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006 >A>	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001 >A>	9889115	Jun 23, 2019	U-1305			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-164	Nov 09, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986	004				ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986	005				ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986	006				ODE-164	Nov 09, 2024
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992	001				M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992	002				M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992	003				M-222	Feb 06, 2021
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912	001	6960346	Jul 03, 2023	DP	NP	Feb 09, 2021
		7560120	Sep 05, 2022	DP		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	>A> 6509376	Apr 01, 2019	DP		
		>A> 7320999	Oct 20, 2019		U-1384	
		>A> 7619001	Apr 01, 2019		U-1384	
		>A> 7803840	Apr 01, 2019		U-1385	
		8399514	Feb 07, 2028		U-1384	
		>A> 8759393	Jul 04, 2018	DP		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	>A> 6509376	Apr 01, 2019	DP		
		>A> 7320999	Oct 20, 2019		U-1384	
		>A> 7619001	Apr 01, 2019		U-1384	
		>A> 7803840	Apr 01, 2019		U-1385	
		8399514	Feb 07, 2028		U-1384	
		>A> 8759393	Jul 04, 2018	DP		
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036	001	9861607	May 18, 2027		U-620	
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036	002	9861607	May 18, 2027		U-620	
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064	001				PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064	002				PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064	003				PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 091471	001				PC	Feb 14, 2018
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	9877955	Jan 03, 2028		U-1969	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9814705	Jan 08, 2024	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001					I-767	Feb 02, 2021
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001 >A>	8534281	Mar 08, 2030	DP			
	9750726	Nov 29, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001 >A>	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002 >A>	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001 >A>	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002 >A>	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003 >A>	9861771	Oct 11, 2020	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	9730890	Jun 22, 2021	DP			
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001 >A>	7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002 >A>	7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003 >A>	7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004 >A>	7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005 >A>	7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	>A> 9913910	Sep 28, 2024	U-2253			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001					M-220	Feb 15, 2021
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9872837	Dec 21, 2031	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036			U-2236	
	RE44846	Aug 10, 2019	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2219		
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031		U-1456		
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026		U-1456		
	8952015	Dec 28, 2026		U-1491		
	8952015	Dec 28, 2026		U-1650		
	8952015	Dec 28, 2026		U-1946		
	8952015	Dec 28, 2026		U-1947		
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031		U-1491		
	8999999	Jun 03, 2031		U-1946		
	8999999	Jun 03, 2031		U-2228		
	9125889	Jun 03, 2031		U-1650		
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033		U-1456		
	9540382	Aug 18, 2033		U-1491		
	9540382	Aug 18, 2033		U-1650		
	9540382	Aug 18, 2033		U-1946		
	9540382	Aug 18, 2033		U-1947		
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034		U-2150		
	9801881	Jun 03, 2031		U-1491		
	9801883	Jun 03, 2031		U-2159		
	9814721	Jun 03, 2031		U-1947		
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8476284	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-2242		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2241		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8563563	Apr 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031			U-1456	
	8754091	Dec 28, 2026		DP		
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2241	
	8999999	Jun 03, 2031			U-2242	
	9125889	Jun 03, 2031			U-1650	
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036		DP		
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034			U-2150	
	9801881	Jun 03, 2031			U-1491	
	9801881	Jun 03, 2031			U-2242	
	9801883	Jun 03, 2031			U-2159	
	9801883	Jun 03, 2031			U-2243	
	9814721	Jun 03, 2031			U-1947	
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8476284	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8497277	Dec 28, 2026			U-2241	
	8497277	Dec 28, 2026			U-2242	
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2241	
	8563563	Apr 26, 2027			U-2242	
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031			U-1456	
	8754091	Dec 28, 2026		DP		
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026		U-1456		
	8476284	Dec 28, 2026		U-1650		
	8476284	Dec 28, 2026		U-1946		
	8476284	Dec 28, 2026		U-1947		
	8476284	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-1456		
	8497277	Dec 28, 2026		U-1491		
	8497277	Dec 28, 2026		U-1650		
	8497277	Dec 28, 2026		U-1946		
	8497277	Dec 28, 2026		U-1947		
	8497277	Dec 28, 2026		U-2241		
	8497277	Dec 28, 2026		U-2242		
	8563563	Apr 26, 2027		U-1491		
	8563563	Apr 26, 2027		U-1946		
	8563563	Apr 26, 2027		U-2241		
	8563563	Apr 26, 2027		U-2242		
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026		U-1491		
	8703780	Dec 28, 2026		U-2242		
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031		U-1456		
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026		U-1456		
	8952015	Dec 28, 2026		U-1491		
	8952015	Dec 28, 2026		U-1650		
	8952015	Dec 28, 2026		U-1946		
	8952015	Dec 28, 2026		U-1947		
	8952015	Dec 28, 2026		U-2241		
	8952015	Dec 28, 2026		U-2242		
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031		U-1491		
	8999999	Jun 03, 2031		U-1946		
	8999999	Jun 03, 2031		U-2241		
	8999999	Jun 03, 2031		U-2242		
	9125889	Jun 03, 2031		U-1650		
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034		U-2150		
	9801881	Jun 03, 2031		U-1491		
	9801881	Jun 03, 2031		U-2242		
	9801883	Jun 03, 2031		U-2159		
	9801883	Jun 03, 2031		U-2243		
	9814721	Jun 03, 2031		U-1947		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9861603	Dec 18, 2026		U-1440		
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9861603	Dec 18, 2026		U-1440		
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9884094	May 01, 2033		U-2238		
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	>A> 7918833	Sep 23, 2027	DP			
	>A> 8512297	Sep 15, 2024	DP			
	>A> 8556864	Mar 03, 2024	DP			
	>A> 8603044	Mar 02, 2024	DP			
	>A> 8679069	Apr 12, 2025	DP			
	>A> 8992486	Jun 05, 2024	DP			
	>A> 9011391	Mar 26, 2024	DP	U-1832		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	>A> 9233211	Mar 02, 2024	DP			
	>A> 9345750	May 18, 2031	DP	U-1855		
	>A> 9408979	Mar 02, 2024	DP			
	>A> 9526844	Mar 02, 2024	DP			
	>A> 9533105	Aug 17, 2024	DP			
	>A> 9561331	Aug 28, 2024	DP			
	>A> 9604008	Mar 02, 2024	DP			
	>A> 9604009	Aug 16, 2024	DP			
	>A> 9610409	Mar 02, 2024	DP			
	>A> 9623189	Aug 19, 2024	DP			
	>A> 9775954	Mar 02, 2024	DP			
	>A> 9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	>A> 7918833	Sep 23, 2027	DP			
	>A> 8512297	Sep 15, 2024	DP			
	>A> 8556864	Mar 03, 2024	DP			
	>A> 8603044	Mar 02, 2024	DP			
	>A> 8679069	Apr 12, 2025	DP			
	>A> 8992486	Jun 05, 2024	DP			
	>A> 9011391	Mar 26, 2024	DP	U-1832		
	>A> 9233211	Mar 02, 2024	DP			
	>A> 9408979	Mar 02, 2024	DP			
	>A> 9526844	Mar 02, 2024	DP			
	>A> 9533105	Aug 17, 2024	DP			
	>A> 9561331	Aug 28, 2024	DP			
	>A> 9604008	Mar 02, 2024	DP			
	>A> 9604009	Aug 16, 2024	DP			
	>A> 9610409	Mar 02, 2024	DP			
	>A> 9623189	Aug 19, 2024	DP			
	>A> 9775954	Mar 02, 2024	DP			
	>A> 9827379	Mar 04, 2024	DP	U-2146		
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8629162	Jun 24, 2025			U-2234	
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8629162	Jun 24, 2025			U-2234	
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8629162	Jun 24, 2025			U-2234	
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	7495103	May 20, 2027	DS DP		NCE	Feb 12, 2023
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027			U-2246	
	8410274	Dec 28, 2026		DP		
	8415387	Nov 12, 2027			U-2246	
	8598181	May 01, 2027			U-2246	
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025			U-2247	
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033			U-2248	
	9670163	Dec 28, 2026	DP	U-2246		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001					M-218	Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002					M-218	Jan 25, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u> N 209939 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u> N 209939 002					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u> N 209940 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u> N 209940 002					ODE-165	Nov 08, 2024
<u>LEUPROLIDE ACETATE - ELIGARD</u> N 021731 001 >A> 9914802		Nov 13, 2020	DS DP U-1666			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 002 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 003 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 004 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 005 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 006 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 007 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 008 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 009 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 010 7723390		Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u> N 021924 013 7691411 7723390		Mar 14, 2024 Mar 14, 2024	DP DP			
<u>LIDOCAINE - ZTLIDO</u> N 207962 001 9283174		May 10, 2031	DP		NP	Feb 28, 2021
<u>LIFITEGRAST - XIIDRA</u> N 208073 001 9890141		Oct 21, 2030	DS			
<u>LIXISENATIDE - ADLYXIN</u> N 208471 001 9440029 9855388		Jan 30, 2032 Apr 24, 2029	DP DP U-1881			
<u>LIXISENATIDE - ADLYXIN</u> N 208471 002 9440029 9855388		Jan 30, 2032 Apr 24, 2029	DP DP U-1881			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	9861622	Mar 07, 2025	U-1316			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001					NPP	Feb 20, 2021
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Feb 20, 2024	U-1770		>A> NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	>A> 9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Feb 20, 2024	U-1770		>A> NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	>A> 9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Feb 20, 2024	U-1770		>A> NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	>A> 9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	>A> 9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Feb 20, 2024	U-1770		>A> NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	>A> 9907794	May 26, 2026	DP			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE >A> ODE-166	Jan 26, 2023 Jan 26, 2025
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP U-2220			
	8192719	Oct 12, 2027	U-2220			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	8323692	Mar 30, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 001	>A> 7358366	Apr 19, 2020	DS		Y	
	>A> 7358366*PED	Oct 19, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 002	>A> 7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 003	>A> 7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 004	>A> 7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N 021410 005	>A> 7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9855215	Jan 02, 2033	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 001	>A> 9504655	Jul 09, 2035	DP			
	>A> 9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 002	>A> 9504655	Jul 09, 2035	DP			
	>A> 9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 003	>A> 9504655	Jul 09, 2035	DP			
	>A> 9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 004	>A> 9504655	Jul 09, 2035	DP			
	>A> 9700530	Jul 09, 2035	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9907793	Apr 04, 2023	DP U-1556			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	>A> 7169791	Jul 04, 2023	DS DP U-836		>A> D-170	Dec 22, 2020
	>A> 7169791*PED	Jan 04, 2024			>A> NPP	Mar 22, 2021
	>A> 8163904	Aug 23, 2028	DS DP		>A> PED	Jun 22, 2021
	>A> 8163904*PED	Feb 23, 2029			>A> PED	Sep 22, 2021
	>A> 8293756	Sep 25, 2027	DP			
	>A> 8293756*PED	Mar 25, 2028				
	>A> 8389537	Jul 18, 2026	DS DP U-1374			
	>A> 8389537*PED	Jan 18, 2027				
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8415363*PED	Jan 18, 2027				
	>A> 8501760	Jul 18, 2026	DS DP			
	>A> 8501760*PED	Jan 18, 2027				
	>A> 9061029	Apr 07, 2032	DP U-1374			
	>A> 9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	>A> 7169791	Jul 04, 2023	DS DP U-836		>A> D-170	Dec 22, 2020
	>A> 7169791*PED	Jan 04, 2024			>A> NPP	Mar 22, 2021
	>A> 8163904	Aug 23, 2028	DS DP		>A> PED	Jun 22, 2021
	>A> 8163904*PED	Feb 23, 2029			>A> PED	Sep 22, 2021
	>A> 8293756	Sep 25, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	>A> 8293756*PED	Mar 25, 2028				
	>A> 8389537	Jul 18, 2026	DS DP U-1374			
	>A> 8389537*PED	Jan 18, 2027				
	>A> 8415363	Jul 18, 2026	DS DP U-1407			
	>A> 8415363*PED	Jan 18, 2027				
	>A> 8501760	Jul 18, 2026	DS DP			
	>A> 8501760*PED	Jan 18, 2027				
	>A> 9061029	Apr 07, 2032	DP U-1374			
	>A> 9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 003					>A> NPP	Mar 22, 2021
					>A> PED	Sep 22, 2021
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	>A> 9907756	Jun 07, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	>A> 9907756	Jun 07, 2029	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001					I-762	Jan 12, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002					I-762	Jan 12, 2021
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	>A> 5792795	May 13, 2019	DP			
	>A> 5948818	May 13, 2019	DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2019	DS			
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 090713 002					>A> PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 001					>A> PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 002					>A> PC	Sep 19, 2018
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8420674	Dec 18, 2027	U-2079			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8420674	Dec 18, 2027	U-2079			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	9610321	Sep 15, 2031	U-1999		I-764	Jan 24, 2021
	9610321	Sep 15, 2031	U-2230			
	>A> 9919024	Sep 15, 2031	U-1999			
	>A> 9919024	Sep 15, 2031	U-2230			
	>A> 9925231	Sep 15, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	>A> 8198262	Jun 17, 2025	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	>A> 8198262	Jun 17, 2025	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	>A> 8198262	Jun 17, 2025	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	>A> 8198262	Jun 17, 2025	U-1360			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001				>A> M-223		Feb 01, 2021
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					NS	Jan 23, 2021
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	>A> 5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
	>A> 8431154	Feb 19, 2023	DP			
	>A> 8536206	Mar 08, 2024	U-1115			
	>A> 8604064	Mar 08, 2024	U-1115			
	>A> 8618142	Mar 08, 2024	DP			
	>A> 9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	>A> 7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	>A> 7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	>A> 7358366	Apr 19, 2020	DS	Y		
	>A> 7358366*PED	Oct 19, 2020				
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	>A> 9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	>A> 9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	>A> 9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	>A> 9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	>A> 9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	>A> 9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	9861638	Feb 10, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	9861638	Feb 10, 2031	U-2012			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	9861638	Feb 10, 2031	U-2012			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9856265	Jul 28, 2026	DS DP U-1467			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9868745	Nov 16, 2032	DS DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 002					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 003					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 004					M-219 PED	Feb 15, 2021 Aug 15, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - CIALIS</u>						
N 021368 004					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9855241	Jan 25, 2033	U-2149			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	>A> 8534281	Mar 08, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	>A> 8534281	Mar 08, 2030	DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	7173038 8642608	Aug 14, 2021 Feb 06, 2022	DS DP U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	7173038 8642608	Aug 14, 2021 Feb 06, 2022	DS DP U-1490			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	>A> 9937223	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	>A> 9937223	Jan 30, 2035	U-1857			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9861630	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm